<SUBMISSION>
<ACCESSION-NUMBER>0001144204-06-007020
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>7
<PERIOD>20060221
<FILING-DATE>20060221
<DATE-OF-FILING-DATE-CHANGE>20060221
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>06631018
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>psivida_6k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
        AND EXCHANGE COMMISSION</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
        D.C. 20549</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>FORM
        6-K</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
        OF
        FOREIGN ISSUER</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to Rule 13a-16 or 15d-16 of</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
        Securities Exchange Act of 1934</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
        the month of February 2006</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commission
        File Number 000-5112</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 20pt; FONT-FAMILY: Times New Roman"><strong>pSivida
        Limited</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
        of registrant&#8217;s name into English) </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
        12
        BGC Centre</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
        The
        Esplanade</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
        WA
        6000</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
        of principal executive offices)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
        by check mark whether the registrant files or will file annual reports under
        cover Form&#160;20-F or Form&#160;40-F). </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
        20-F&#160;<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
        40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(1):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(7):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark whether the registrant by furnishing the information contained
        in
        this Form is also thereby furnishing the information to the Commission pursuant
        to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">x</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
        "Yes"
        is marked, indicate below the file number assigned to the registrant in
        connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
        </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to the requirements of the Securities Exchange Act of 1934, the registrant,
        pSivida Limited, has duly caused this report to be signed on its behalf by
        the
        undersigned, thereunto duly authorized. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
        February 21, 2006</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

            <tr valign="top" bgcolor="#ffffff">
              <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td colspan="2"><font size="2">pSivida Limited</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:&#160;&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/
                Aaron Finlay</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="FONT-FAMILY: Times New Roman" size="1">&#160;</font></td>
              <td align="left">
                <hr style="COLOR: #000000" align="left" noshade size="2" width="80%"><font size="2">Aaron
                Finlay</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Chief
                Financial Officer and Company
                Secretary</em></font></td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
        INDEX</u></em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" valign="top" width="15%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                  99.1:</strong></font></div>
              </td>
              <td align="left" valign="top" width="62%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Uveitis
                  long term trial results positive</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="15%">&#160;</td>
              <td align="left" valign="top" width="62%">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="top" width="15%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                  99.2:</strong></font></div>
              </td>
              <td align="left" valign="top" width="62%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Diabetic
                  Macular Edema trial with Retisert</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">-2-</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>psivida_ex99-1.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><img src="logo.jpg"></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 171pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 31pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 31pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 31pt">&#160;</font></div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="justify" valign="middle" width="43%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ASX/MEDIA
                  RELEASE </strong></font></div>
              </td>
              <td align="right" valign="middle" width="43%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>21
                  February 2006</strong></font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>pSivida:
        Uveitis long term trial results positive for pSivida</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong><em>Second
        set of follow-up trial results announced today</em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <div>
          <hr style="COLOR: #000000" align="left" noshade size="1" width="100%">
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Global
        bio-nanotech company pSivida Limited </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(NASDAQ:PSDV,
        ASX:PSD, Xetra:PSI)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        today
        announced that preliminary three year follow-up data from </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bausch
        and Lomb</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8217;s
        multi-center, randomized, dose-masked clinical trial of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>&#8482;</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        for the
        treatment of chronic non-infectious </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">posterior
        segment uveitis </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">has
        been
        published. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Global
        eye health company, Bausch and Lomb (NYSE: BOL), exclusive licensee
        of</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>&#8482;</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
        conducted the study that showed the recurrence rate was significantly lower
        in</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        eyes
        receiving Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>&#8482;</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        than in
        non-implanted eyes. This study involved 278 patients from 27 hospitals in
        the
        United States and one in Singapore. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        receives royalties from sales of Retisert&#8482; which is presently priced at
        US$18,250. Covered in the United States by Medicare and Medicaid, Retisert&#8482; is
        co-marketed in the United States by Bausch &amp; Lomb and Novartis.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div align="center">
            <table bgcolor="#ffffff" cellpadding="0" cellspacing="0" width="100%">

                <tr bgcolor="#ffffff" style="LINE-HEIGHT: 1.25">
                  <td valign="bottom" width="30%" align="center">
                    <div><em><font size="2"><img src="pic1.jpg"></font></em></div>
                    <div><em><font size="2">Surgically implantable Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 7pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font></em></div>
                  </td>
                  <td width="70%"><font size="2">Posterior uveitis is the third
                    leading cause
                    of blindness in the United States where it afflicts an estimated
                    175,000
                    people. Approximately 800,000 people have the disease worldwide.
                    Uveitis
                    is a chronic auto-immune disease in which the bodies own defences
                    attack
                    the inner lining of the eye (the uvea). <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>&#8482;</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
                    approved by the FDA in April 2005, is the only FDA approved drug
                    for this
                    disease. Retisert&#8482; is surgically implanted into the eye and is approved to
                    release a constant amount of the drug, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">fluocinolone
                    acetonide</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
                    over a treatment period of 30
                    months.</font></font></td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        study
        concluded that at three years control of uveitis in eyes implanted with
        Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>&#8482;</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        was
        still significantly better than in non-implanted eyes, but was less effective
        than at two years and that some eyes may need to be re-implanted between
        24 and
        36 months.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;These
        results confirm the long term benefits of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>&#8482;</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">in
        the
        treatment of this devastating disease,&#8221; said Mr </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Gavin
        Rezos, CEO of pSivida Limited. &#8220;The possible need for an additional implant at
        between 24 and 36 months is consistent with the 30 month label from the FDA&#8221;.
</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        this
        study, patients were randomised to receive either a 0.59 mg or a 2.1 mg
        Retisert&#8482; device. Data presented was the aggregate of the two doses. At three
        years, the recurrence rate of uveitis was 33% in the eye receiving Retisert&#8482;
        compared to 57% of fellow eyes (p&lt; 0.001). A greater number of eyes receiving
        Retisert&#8482; experienced an improvement in vision of at least 15 letters (three
        lines on an eye chart) compared to fellow eyes (22% versus 6%, p&lt;0.001). 45%
        of eyes receiving Retisert&#8482; required an operation to relieve elevated
        intraocular pressure and 92% developed a cataract. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cataract
        surgery is a relatively uncomplicated and established procedure with a high
        success rate.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        abstract (#1523) detailing this data is available on the website of the
        Association for Research in Vision and Ophthalmology </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.arvo.org</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
        Fuller
        data will be presented at the ARVO conference in May 2006.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>-ENDS-</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div align="left">
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="justify" valign="top" width="30%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                  Limited</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brian
                  Leedman</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
                  Relations</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                  Limited</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  + 61 8 9226 5099</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">brianl@psivida.com</font></div>
              </td>
              <td align="justify" valign="top" width="40%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>US
                  Public Relations</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverly
                  Jedynak</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
                  E. Janis &amp; Company, Inc</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  +1 (312) 943 1100 ext. 12</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</font></div>
              </td>
              <td align="justify" valign="top" width="30%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UK
                  &amp; Europe Public</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Relations</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                  Swallow / Helena Podd</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Citigate
                  Dewe Rogerson</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  +44 (0)20 7638 9571</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">mark.swallow@citigatedr.co.uk</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTES
        TO EDITORS: </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div align="center">
        <table bgcolor="#ffffff" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="#ffffff">
              <td width="70%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>What
                  is Uveitis?</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An
                  autoimmune condition, Uveitis manifests itself as an inflammation
                  inside
                  the eye, that can lead to sudden or gradual vision loss. It can
                  be caused
                  by diseases such as multiple sclerosis, rheumatoid arthritis</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                  is a global bio-nanotech company committed to the biomedical sector
                  and
                  the development of drug delivery products. Retisert&#8482; is FDA approved for
                  the treatment of uveitis. Vitrasert&#174; is FDA approved for the treatment of
                  AIDS-related CMV Retinitis. The technologies underlying both of
                  these
                  products are licensed to Bausch &amp; Lomb.</font></div>
              </td>
              <td width="30%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><img src="pic2.jpg"></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        owns the rights to develop and commercialise a modified form of silicon
        (porosified or nano-structrured silicon) known as BioSilicon&#8482;, which has
        applications in drug delivery, wound healing, orthopaedics, and tissue
        engineering. pSivida&#8217;s subsidiary, AION Diagnostics Limited is developing
        diagnostic products and the subsidiary pSiNutria is developing food technology
        products both using BioSilicon&#8482;. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida&#8217;s
        intellectual property portfolio consists of 70 patent families, 74 granted
        patents and over 290 patent applications.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        conducts its operations from offices and facilities near Boston in
        Massachusetts, Malvern in the United Kingdom, Perth in Western Australia
        and
        Singapore. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        is listed on NASDAQ (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSDV</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
        the
        Australian Stock Exchange (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
        and in
        Germany on the Frankfurt Stock Exchange on the XETRA system (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>German</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Symbol:
        PSI. Securities Code (WKN) 358705</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
        pSivida is a founding member of the NASDAQ Health Care Index and the Merrill
        Lynch Nanotechnology Index.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company's largest shareholder and a strategic partner is QinetiQ, a leading
        international defence, security and technology company, formed in July 2001
        from
        the UK Government's Defence Evaluation &amp; Research Agency
        (DERA).&#160;QinetiQ was instrumental in discovering BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 7pt; FONT-FAMILY: Arial, sans-serif"><sup>(TM)</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        and
        pSivida enjoys a strong relationship with it having access to its cutting
        edge
        research and development facilities. For more information visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.QinetiQ.com</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
        more
        information, visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.psivida.com</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
        document contains forward-looking statements that involve risks and
        uncertainties.&#160; The statements are indicated by the use of words such
        as
        "believes", "expects", "anticipates" and similar words and phrases.&#160;
        Although we believe that the expectations reflected in such forward-looking
        statements are reasonable at this time, we can give no assurance that such
        expectations will prove to be correct. Given these uncertainties, readers
        are
        cautioned not to place undue reliance on such forward-looking statements.
        Actual
        results could differ materially from those anticipated in these forward-looking
        statements due to many important factors including: our failure to develop
        applications for BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 7pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        due to
        regulatory, scientific or other issues, our inability to successfully integrate
        CDS&#8217; operations and employees; the failure of the CDS&#8217; products to achieve
        expected revenues and the combined entity&#8217;s inability to develop existing or
        proposed products; the failure of the Bausch &amp; Lomb/Novartis co-promotion
        arrangement to provide faster royalty growth. Other reasons are contained
        in
        cautionary statements in the Registration Statement on Form 20-F filed with
        the
        U.S. Securities and Exchange Commission, including, without limitation, under
        Item 3.D, "Risk Factors" therein. We do not undertake to update any oral
        or
        written forward-looking statements that may be made by or on behalf of
        pSivida.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````6@``_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0(!`0$"`@(!`0("`@("`@("`@,"
M`P,#`P(#`P0$!`0$`P4%!04%!0<'!P<'"`@("`@("`@("`$!`0$"`@(%`P,%
M!P4$!0<("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(
M"`@("`@("`@(_\``$0@`8P$3`P$1``(1`0,1`?_$`-4``0`"`@(#`0$`````
M```````)"@<(!@L#!`4!`@$!``$$`P$!``````````````<$!08(`PD*`@$0
M```%`P,"`@0)!@D("P````$"`P0%``8'$1(((0DQ$T$B%`I187$R(Q6U=C="
M8C-U%CF!L5*S-#47=SB1H4/3E397&,&"HE-C@R2T5;89$0`!`P($`@8$"0<*
M!04````!``(#$00A$@4&,0=!46%Q$PB!L2(R\)&AP4)R,Q0)4B-SLS05-M%B
M@J*RPH-T-3>2TI-5&$-3)"87_]H`#`,!``(1`Q$`/P"_Q1$HB41*(E$2B)1$
MHB41:5\O^X+Q5X.VV,UGO)C6&FW2)E8#'K(0?7#)Z?-\ADB.\"F'H"BFTGYU
M5-O:/E/LA8?NK?>EZ,RMU(`X\&C%Q[A\YH.U1%N>ZWW/LX,9*_.(W;$D5L/L
MTC.(JYKO<.&TE*-RD\P%$&I3M0/N+U*5(5-?0(]*N0TZ%IH]XK\/AT*)9>:6
MY;UOBV%@XQ=!=Q/HJWT4JI`.UCW(F/<0Q5>4K.V0&-,OXFD4XO)MEIK*+-"G
M<%.=NY:F7*54"'!,Y3$.&XARB`B/0:H]0LO`=2M05GG*[F,W<5HY[F>'+&:.
M;ZC\AP/`A2D50*3DHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B+P.7+9DV</'C@C1HT(=5TZ5.5--)-,HF,<YC"`%*4`
MU$1Z`%%^.<`*E5Y^67=\O[+F2'7#GM1VB.>,]2)C-;DS4FDFO;%L)`;RUED%
M5_H%A2ZZN%1!$HAZH*FZ!>;;3@T9Y<&J!-T\V)[JY_=^B-\:X.!?]!G6:\#3
MK/LCMX+,7![LTV%B"YC<C^8UQ?\`-CR_N189"<O*;,K(PT.[5]82LD'P""RA
M->BZI`T_T9"`'7CNM3<X96>RU7797)^WLY?O=^[[S=G$N=BT'L!X]Y]`"EVR
MQDBT\*8KO[*=X/DH:T,;0SZ6F71S%233;1[8RVTNN@:FV@4@!XB(`%6Z*,O<
M`.)4K:KJ,5E:OGD-&1M)/<!508>[OX?F8SCUFWE)<D:2-?<L+TD9BWVVTP*$
MAX]TX2*.IOR#N%EMOQ%`:NFLR@O#1]$*$?+[H\C-/EO9!0W+R0.P5^<E6%JL
MZG]*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB418HR5F
MFPL2J1*5Z2"S(\T"IH\J3=1?<"(E`^OE@.FFX*@/G7YE=J<OG0C69'QFXS9,
MK'/KEI6M.'O!733M'GNJ^&*T7T;`RUC[)R"RMF7(C*K-@`SN/'<DZ1*/0!.B
MJ!3`'QZ:?'5YY3<_]H[XA<_1KILSF"KF8M>T=98X!P';2G:N.^TN>V-)&T]2
MYG+S41;[!:4G)-"(C4!*"[]RJ1%$@F':&IU!``U$=`J2-P[ET_2+1UU?2L@@
M;2KWN#6BIH*DD`5."HXH7R.RM%3V+A_]KF+?^(L+_M)I_K*CC_R&V'_W2T_Z
M\?\`S*L_=-U^0[XBG]KF+?\`B+"_[2:?ZROS_P`AMA_]TM/^O'_S)^Z;K\AW
MQ%0Z\V^+G.'N)7FGBVU^2ME8<X4MWI$[VC;2DI&4O":9[?,UD#%;HH!YFFA&
MP*@F'B?S--*DK9/,;;FL1ODTVYBNS'0.,;VO#2>`.4FA/;Q4)\P-C;CU:<0.
MD;!9DX@9L[AVU`!KU5`'352!<?>-?%+MWXA0L[&$`PQS;1-@SMS.1!:8G'A2
MZ>:[<B`K.%!_)(`;2AT*4`JS<R.:>B;9L3?:O<,MX!A5QXGJ:,2X]C02L_V9
ML6UTV$6]E'3K/$GM<?@.I98L7D9BS(]RI6I:DNN]F%TUE44SM%T2&30+N,.Y
M0`]'A4%\J_.3L/>>M#2M*F?)<.#G`&-[00T5.+@.A9Q?;?NK>/.\4'>HD^Z9
M+7ES-S)B7M387EEHT+]]EO'EW>C;<)+=L./<E.@V5$!`/.?+%`4TQ'UA*3\D
M1K;NPI$TRGN"UZYFF?5[F/1K<T#_`&I7#Z+!P'>3C\705-5C?'EHXDL"S,86
M#$)P-EV#&LXFV(A(``J#-B@5!,HB`!J;0NIC#U$=1'J-6Q[RXU/$J7=.T^*T
MMVPQ"C&``#L&"YK7RJU*(E$2B)1%^;BZ[=0W?R?37SG%:=*+]KZ1*(N&J9$L
M%)P=HK>L4FZ2.*2C8T@U`Y5`-M$HE$^H#KTTJ-IN<FT8YC$_4+82`Y2TS1U#
MJTH1FK6N%.M5@TZ<BN0T[BN95)*HTHB41*(L+WGR.X^XYGW%JY`SA:5D7,S3
M25=V]+7#%1[U))<NY,YD7:Y#@4X!J41#K7,RW>X5`)"LE]N;3K63PYIF,=U.
M<`?B)63K<N2WKP@XNY[3G&ERVW-I%7AYY@X2=LW:!OFJ(K(&,0Y1TZ"41"N)
MS2#0JZ6UU'-&'QD.:>!!J#W%?:K\7.E$2B)1$HB41*(E$2B)1%CW(&/K5O:/
M,O.VLPN64B4'`P)7Y3"D18Y-0`QBB`@4QBAN^*HDYM<I="W-9E][:0W4\+'F
M(3#V0XC@2.#20,W8JZQOI(7>RXM!XT43-YDNS$E]P.289I`VLZ65U:0MO2Q)
M%H4R!"^>FH4#&,5-8H]2CTU\.M>?_F8=>Y>;MMMR6++.T<YV$5I.)8_9`SM<
MT.<6MD!Q!P.-,>$HV8BNK=T)S.[7"A^`4K,I"6IG+&L>WF$E5;;NYJS>BDDJ
M*2H`8"."AO+X"4>@UWW:WMK0>9^RXX[L.=97L<<E&NRG&CP*CJ.!48Q32V=P
M2WWFDA1<<H</6OA^[+?8VFHX^JY]D=P9FY4\XR*B2OECM.(`(E,`@.@^%=#O
MGT\N&@\N]<M8M)+Q#<1%Q:\YBTM=3!W$@]1X=:D_:^KRW<;C)Q!6.,+6+&Y(
MR;:UG2[A1K%RJBPOU$="JBF@W4<"4IA`=HFV::Z=*@_RM\K+'>F^[/2+QSFV
M\SG%^7!Q#&.?0'&E<M*TPJKEK=ZZWMG2-XA3%8PP[96(6TPULQNX;HSBB2LA
M[0X,X$3HD$A=!,`:=##7I*Y'^73;/+R":+1VO:V<M+L[R_%H(%*\.)40:EJT
MUV09.A1CY%NF<Y`9L>(M5V:T!;BJQ(")DGQ(YB9DS5`JFY4PAH=<P:CIUT$`
M\`KH^YR;^U7FWS0?'$Z)UE9N<(HYY1#$8XW`.JXD>U*14TQH0/HJ1M/MH["R
M!-<SN)`J<?Y%MV)[<PIBD<L-\2P[S++I-5C8UHVRH9S]<2CY06[%BW<")PT6
M-M\U4?53)N.;0I1&NY'RV<E]$L[&#5G:?96NH.#_`&K4YV!A)`ROJ0ZK0*T)
MQJ`HNW7K\L$;LI?)T!IXN=T#LQ^(8KU^&/$__EZAK\R'D&11O3DYR%DQN/D)
MD@H")5Y%4!\B+8[NJ<;&IF]G:DZ:E`3B&XPZ;7W-QGP'NC@L*VIMK[BU\LIS
M7$QS/=V]#1_-;P'QK=BJ59:E$2B)1$HBBZY(\GKK>77+6/CR94@;?@5#-I28
M;Z$=/':8B54"*=1(D0?5#;H(B&NNE=%?G;\]>NNUV;0]OS&WMK<EDDC,'R/&
M#@'<6L:<!EH7$5K2@4E[;VS%X0EE%2>`Z%IRE>=X(NPD4;NE$WP&U!\$@[\S
M=X_.\S4:ZTX.:.Z89Q<MO;@25]_Q9*U[\U5F!L8",N44[@M_^+G)J=N"<;XX
MR1(_63N1`0M:XU"E(J=4A1,+=<2Z`8Q@#4AM-1\!]%=P'D0\\FIZ[J3=O;AD
M\2:0?F)C0.<1CX;Z4J2/==Q)%#4D+`=S[;9$WQ8A0=(4AE=P"P)0Q7%@S+CK
M(LW*M\=2*T<O.*N$794D]AD1?>8!P];P$O6O--O+RJ\Q9]YSW4>FSF%UT]P=
ME%"TR$@\>!&*F&WURT;;`%XKE^93.UZ65#R41*(E$5)7O7<">8>>NX!D/)&'
M^-MR9(L:2@;9;,;KCFB"K19=K'BFL0IE%2"(D-T'I67:3>0LA`<15:1\]=@:
MWJ6O.EM8G/CRMQ'#@%:/[;MA7AB[@GQ<Q[D"VG-G7I:-IL&5R6N\(5-TQ=)B
M?<DH4@F`#!KZ!K'+YX=,XCA5;2\MK":UT*WAF:6O:P`@\05NW5(LW7$<@.G+
M&P[V>LUS-7C.(DE6CD@[3IJ)LU#E,4?0("&H5]QBK@J+47EMN\C`AI]2Z_KM
M_P#.OFA?/.#BQ9MY<I;WN>T[CO>+:7!;KV<76:/6JBB@'163,&AB&TZ@-9IJ
M%A$V(D#%=>O+3F+K5UKT$4L[W,<\5!<<<1VKL,ZPA=BZ41*(E$2B)1$HB\2Y
M=Z"Q-@*[B&#RQZ`;4--/X:X+IF:)PI6H.'7V+]:<5#YF:T7L5:ZSX^#HC':+
M=ZF52XF,W[<N<#&.4$A1%0W0X]1'3II7G0\SG+J>QT!T_P"X+;36LE'YZ*Y,
MKC6HRY"]V!.-:84Z%+6C78?*!XKGX<"VGRT6[?'N_+<M3C%#WE>T^VMNUK(9
MR2MQ7$^6(W:,V3%RLH=15100`I"$^&NVS\/W6)+[E3I^:I='XC/^&5]/B%`H
M]WI-%;74DCR&L`J2>`%,2HV[_P"3]B<Q[$Q;GW&+1VUL&X%KKC+87>E*FX>M
MH&X%8D'GEAU3(X%$5"$-ZP%$->M:"_B[6KH=P:8T\?`>?ZZN/)O<UMK&FNNH
M*^&7D"O\TT7+.*7X]6-\K[[/6K5+\/K_`':T_P#Q?U,BSS=7[`_T>L*82[7:
MC"U+F?)"(*LX]ZJF(=!W)MCG#3^$*](7,'4'6F@W<[?>C@E<.]K''YE$%JS-
M*T=9'K4,N$+?>3R]Q.$L71^4"MRH>:C(RGU:5H=4QS;B#O)O$^@@/P:5YKO*
MWM*XU>>[E;I$&JAN6HFG\'PR234>TW-FH:\:44OZU.(PT9RSN%5+CC2`:-;(
ML<'EHM+8?0K8PLH-!;VQ*-.L!B'*BN83".I3"`F`?`1#PKT5\C]-=9[2LX3;
M,LRV,?F6/,C8\3[(>2<W76IX\5$FIT?<%U<V/$BBR54JJD2B*+GN$]U;#W;I
MN+&=N9/QY<E[.<H,Y%[$.((L<9-NG&K(H'*M[:X1'4PK`(;=:N5CIC[@$@@4
M44<QN;=EMJ6-D['/\0$C+3H('21UK"%X=]WB19/%C'')*8A)TDWE\\L3'6#"
M@P/<KHD0^48*N'/E+'1;-1.GT6.;0=="@(Z@'U'I,CY"P='2K;?\\M)MM(CO
MI`09:Y689C0D5-#0##C\2PWQ&]X>X]\B\QVUAS(N+9;`[N^G2<?9EX/I%E)1
M*LBX.";=LZ4;E3,W,L80(0X@)-P@`B&NM5%UH<D;,PQHK#LSS%Z7JMZVV>PQ
M.>:-)-17H!X4K\2L#S*ZK6'E72`[5FS9=1$WP&(D8P?YPK"=R7;[?3II6>\R
M-Y'>&DA;%Q-!<!VJOHT\F0FFWUJY\MM(/2?6CPP]2D6<_2G$?D$1KR"6/AWV
MMM^]NHR689W'H#G>T3Z"2IZ?5D7L]`4[,EC.PIZQ_P!B#0#0]L+-018HII)@
M"113T(JD8@!H</G`8!UUZUZM]9Y*;4U7;'[E=;1&Q,8:T!HHT4]ES2.#AQ#@
M:DXUQ4'QZA.R;Q*G-51R6%Q`S"G=3247<M+5:6[(`K'RRZGG+K@S<@8BA$4-
M=`4`NH;A#QKIGY2?AR\P(-Q,O'21VD5M/F8]QJYPC?5K@QM:!P%1F(P.*D*^
MW=:F'+0N)&/I4KQ=0*4##J8`#</AJ-=^C0:8\5%ZTUD>:EAQMQ/;;5M664=L
M7QV)UB@T\LRA%_($P:JZZ:]?"NM?6OQ-]J66LR::ZSN3)'*8B1X="0[+7WZT
MKCPK19A'LV=T8?F%"*]*Y#S0Y6VUPJX_W3R'O&S9:^+7L]Q'HS4/"@V%Z1.1
M>$8E6_\`5J)$V$.H7=J;TUV9VEL9GY0:*(]Z[KCT33W7;V%[6D5`I7$TKC@M
M-^`O>(P+W!,K73B''=@7+8ER6S"#.%6GBQI47K<CLC11-'V)RL;>05`,.H`&
ME55]I;X`"36JPWEYSCL-QW#H86.8YHK[5,<1PH3UK:+G9S?QGP$PJAFO)\+)
M7-%OIAA"15MQ'LHR#IV^!0^J8.U4B;4TTCG/ZW@%4]G:.F?E"RK?F^+;;]A]
MZF!<VH%!2IKWT'`+!?;W[IN,.XO/9+B,6XJNBS&.+6D<XG9Z="-*V45DU5DT
M6Z0,G"QA/H@<PZ@```5SWVFN@`S$8JP<N>:UKN5T@@C>P1@5+J4QK@*$]2PM
MS3[X6`.$6?KBX]W_`(FN^Z[EMQA&2#B;B"Q(L5$Y1N+@A2^UNDC[B@&AM2_)
M7+::.^9F8$*R;ZYYZ?H%^;2:-[G``U&6F(KTD%2@\<,XP');!>+\]6M$/(&W
M<J1*$O#PTAY(/6Z#@3`4BWD'.3<&WKM,(5;KB$QO+3T*4MM:ZS4[".Z8"ULC
M:@'B.^BTN[BO=2P1V[(VV8V\XM[D7*M[)*.;8Q=$*-TG7L*1_*,\>+N!V-T!
M/J4@B`B<P"!0'01"IL=/?.<.`6&\QN:FG[;C;XU72.X-'&G6>H>OT+2?C=W]
M.,7*U*\,37_;3WCG?=PQ,FC9JTV^9NH.47,Q5`K<)!'RRH+F'H0BI2@;P`VO
M2JV?1I(B",0L'VQS^TG66O@>##(6FF8X'`X5PH>_XU4U[:P"'<%X?@(:"%_Q
M&H?^8I63ZG]@5ISRE_B2W^NWUA=F^(@`"(CH`>(U'B[3%`GR]]X*XG\;+^G<
M6X_MJ5Y$7A:RYVESR,&X9M(%F[2'11`L@Y$P+J)CJ4_E$,4#`(;M0J\VFB2R
MBIP"@3>GF$T?2;@P,!F>,#EI0'OZ?0*=JP)A_P!YJXY77=4=!YAP;<F(H"04
M*FM>R+ME/-&0F-MWN$6I4E@3#74QB%,(!Z*YY]OR-;4&JQW0O-!I5Q.(YHW1
M@_2K4#O%`?BJK)%JW3;E\6U`WE9\VVN2U;H:-W]NS[-4J[5XS=)`LDLDH01`
MQ3E,`@-6!S2#0K9:VN8YHQ)&0YKA4$<"#P*^_7XN=*(E$7X(`("`]0'QK\(J
M$43>:<<&CHN\WL?Q]?6R$>[56&_AN)=ZAY`.A$RWLBO3:H!O#\G6N@/S/<F1
M:Z??S6^VIK7PI'.^]_?'R,RA^+_!.%'@UI]&O8I1T;4<SF`S`U'NY:'APJM%
MN3'&WDISEQ/Q:XO8CNM:SN/\W=%P'Y8SS<"@+>/8>SR3$%1$P"H57><J*.FT
MRH%,;U2UV#?A<[IM9^6(B!K+;SR-(^M1X^/-\A6O?F&VEJ>L7L-K`[);R8R$
M=0I3YZ#KHML<\8*QIQGM3!6#\00!;:Q]84&Z;PL:!S**'.=YYJSA=0_K*++J
M"*BAQZF,(C6EWXN5PZ7<&FN=Q\!_]M3/RFT*VTS3_NUNW+&R@`]'$]9/$E>O
MQ2_'JQOE??9ZU:K?A]?[M:?_`(OZF19ENK]@?Z/6%*SF:<0MS%.099R.B:,2
M\3+UTU4<(BW(`:^G<<*]`OF1W-%I&P=3NI,`+:1OI>TL;\K@HITF(ON6`=84
M3N&+*<3L1-R2N$WF5VI54T6SQO-JQ!6BJ:8G.F()?I!,!RCJ/A7G^\K_`"S?
MJNGW%T_0)=8CSAK7,N76XC(%7-(;[Y.9I[*8<5*FM7N1X:)1&>UM:J82QXM"
M$LZV8EM#C;Z+!DW3)!F7,Y,TT3#Z(53]3B0>@F'QKT9\L-"BTS;MI:QP&V;'
M$P"(N+S'[(]@O.+BW@7'CQ427DA?*YQ-:GCUKE59TJ9*(J</O17XH\1/U#=7
MV@PK+MM>Z[O"TD\V?[7:_4?ZVK%_9D[1^"><>'+LSYR-N.<G8:*EWEL638,7
M(*QJ;4K!--95RLX(!E!U.N/EI$$I`ZB;<(]&K:F^%^5F"X^2O)ZQUS3OO5\Y
MSP#E:T&@`&/S\!VJ%SF]QZ<\/^6F:\#QDFX=-,8S0&LJ=5'1TK&KI)2<>L8Q
M`+]*4BA2F,`!ZQ1$*O%G<>-"">D*"-_[9_<.N26\9.5CO9/30XCTT*[)CC#D
M0N9.->"<FKKE?J9"L^WY.06UW`HN]BD55]=?'US&`:CR]MVYG1N%1B".Q=G.
MUM4^^:;#<5]]C7>D@%1;Y\Q+*8GOR48*-#?LO,K*N+6D@*(HG05,)Q1$PAIY
MB>N@A\'7PKRW><'R\7^P=V3,R'[C.XO@?CE+2:Y*_E,X$=QX%;#;?U=EU`/R
MAQ"RC@[EE<6.$6-L7@BI=-F-]J;58!`9!@F'0`3,<0!1,OH(;J`>`^BIW\J_
MXAFK[0CCTO6FNN].;1K7#[6(=`!.#V#\DX@>Z:8*UZYM-D]7Q8/^0J4JT;QM
MJ^X-K<=J2Z4S$//T;E(?FF#YQ#E'02G+Z2B`"%=\FP>8>C;HTQFH:7,V>W?P
M<T\#TAPXM<.D$`A1E<VLD+\KQ0A<FK,U3J!"Z?Q5N#[PK?:%>27?W^X%S_G'
M_K2IWM?V4?5^92@\Z<0-\]<.N2F)EV9GZUWV?-$B6I"B8YI)HT,_8[0#J(@Y
M03$`KUQV<N25KNHK5S?>C_?]&GM^)<QU.\"H^4!46NQKE93%'<HP.FY*)&N2
MTY:T9-,0#HI)L3*H[M1#3:NV+68ZU%GMZ]2T+\OVJ_<]SL:>#ZM^,?RT4PWO
M0V5&Y(3BEA!NMN=.WL]=<J@!@]5-HV3AVPF+^<+E;0?S1^&K7MN,YG.4R>:[
M5PVVM[4<22X^B@'K*V>]VJQ`A:'#2_\`+J[<2RF9;P>@BY,`!NCK>2)%H@4?
M$2^;YP_*(U3:_-FFIU++O+)HHM]!,W3*\_$,/750*^\"_O-,G_=NTOLTU7W0
M_L!\.E:]>97^)7?5;Z@KB7:C_=R<//N5&_QJ5B6I?;N[UNARF_ANU_1A4F^]
MQDR0R)W*N23I\Z,[:6`M'6W"H:ZE0;P\8D4Z9`]`"N=0XA_*,(UE^C,#+<%:
M,\_-1?=[HE:3@PAH[``/GJ?2II[$]WQP!>/`&U;YF;GGK<Y.SUH)W4YN_P!N
M!>'2>N8[ZU28J1PD\OV8I3%3,8H@H`ZFW:]*M#];D$]/HUHITL/+KI<FWVR$
MN;<F/-FKA4BH%.KHZU7B[:>O_P"@7#L#?."_88#?*!U`&K]JGV!6L_*0?_9+
M?ZX]85]?NHY%RKC+@?G^;PG!2T_D^8C$X6UF\(T<O9)!2:=)QJCE%-H4RFJ*
M2IS[@#U=-:P>R:TRC-P78GS*O;N#1)G6H)E(H*8D5-*CN"I8]N;M2Y;Y>\A6
MN.,NVC=N#\56]&N)B];P>P;I@Z<))*IH)M&2DHB"0N%U%0$3"!MI0,;01TK+
M[W5XXV>QB5H_RYY*7^KZD6WS7Q1`$DTH3U`5'3Z<`5ROO#]LRS^W9?\`BLV+
M[QE+MQEEMF_&/1FSM59./DHLZ?G)"JT10(HD=-8IB&$@"`Z@.O0::3J;IZAP
MQ"_.=O*6#;<D;[=Q=%(#[U*@BE>`&&(Z%8]]W,R;<%\]O]2U9]XM()8GNZ:A
M;<765\SRHM5)O))($`>I2)'<*`4/``'I6/:[$&SU'2%L_P"7#5Y+K;H:\U,;
MRT=U`1ZRI\*LRGQ*(E$2B*+/)N3N*&0<T9IQ_:TU(Y+S%B4K%7-6-H.;6:K1
MK=PW+M<%;J$,1<$_5*Y!(1%(PAO`-:ZZ_.'Y>]`@AEW'-8WEZV4_GF6]P6!H
M#0,_AEKJ@T`=EX>]3B5<-I[XM[F\?812L$L5*@C''M[.GJX+">)LX/<,7=+R
M-IM592SI@VU[;3U4I5C)%$13-YB0"4JR>HAN`N@AXA74MY?O-5/RRW%/-I<;
MY=,G/M0RN`=05RG,T4#VU(S!M",".J5=4T,7D(#R,XZ0OI\BLTQ&:YFUY>)A
MG,($(T6;NF[DR9Q,=18%`$HICU`/CJZ^=+S/:9S.O[.YLX)(/`C<UP>0<7.K
M@1T#T+\VYHS[-C@X@U*X-AJ^V&-,CV]>LFR6D&,/[3Y[1#8"IO.:J(!MWB`=
M!/J-1'Y8^:]GLC>MKK-TQTD4&>K6TS'-&Y@I7#BZJKM:L77-L8VX$T]:RIGG
MD]+Y@9(6W'19K7L]%4JSMN94%7+PY!]3S1*!2@4OB!`]/B/2MA_-AY[;_F+:
MMTRUA-IIP<'/&;,^0CAF(```XAHZ>)-`K3H>V&VCL[CF?\@68^/.+,=Y%*WD
M&-EW1#0T(**CBXG<T9%G(/4A*82D;MR$W@(AJ;0=`#IK6SODYY%;1W;&RX@L
M+^WM8,I,TES2.65M*AL;6"H-*NH:`85JK+N'4KB#`N:2>@#$#O4DX!H&@=`#
MP"NY\"BCU*_42B*G#[T5^*/$3]0W5]H,*R[;7NN[PM)/-G^UVOU'^MJD/]VP
M_P``MR_W@7%_,M*MFO\`VWH4M>6S^'!]<^H*O+W^$4D>YKE\4R;16@K4.K\9
MAB=-?\U7_0OL/AVK6;S&@#<S^YO]D*YGVMS";MW\.Q,.H_L)"=?D;Z5AUZ29
MG=Y]:WDY:@#;]K^B9_9"W0NZSK:ON#=V[=<2E,1+P/7;J%ZD-Z#IF#J0X>@P
M#J%8%O\`Y>:-NC3'Z?JD+9[=XQ#AP/06GBUPZ"""%GUK=20O#F&A"BOSOQ4G
ML8HO;JM1<]R6.B(F=$,&KZ.3'TJ@'11,/#>'4/2'IKH3\V/X?VJ;*BDU72'&
MZTUI)<#]I"/YU,','#.*$89ATJ4-#W4RX(9)[+_D*X%QURW)8KO^,,+DYK4N
M-9)K<L;N'RM%3`F1P`>`'3$0'4/$NH5$WDJ\Q-[L3=L3'/)L+I[8YF5P]HT;
M(!T.836O2VH5;N326W4!(]]N(_D4V0"!@`P#J!NH#\0UZ>&N!%0H:4"-T_BK
M<'WA6^T*\DV_O]P+G_./_6E3O:_LH^K\RGL4(14ATU"[B*`)3E'P$!#00KUM
M*""NM!RE`N^%7<UN&.0<^Q)8)RV@^CG>@I@6)"=2DDAT#40*+-P`#\59_$1-
M:]X76+JL)T+>+@#01S5_HUJ/DHMSO>'LLJ7]W!)"WT'`.8C%-F6VPC"%_ERK
M0UQG\/$3`^('\&E4V@QY8*]:S'S+:F+K<38@<&,:/C]KU.5P_MJ8<6P-P1XO
MXT>-RMY:+M2.=SA"@4-7TJ091;7;Z=S@0'Y*Q2^DS3./:MT^7&D&QT.WA/$,
M!/><3ZU3*]X%_>:9/^[=I?9IJR_0_L!\.E:1>97^)7?5;Z@KB7:C_=R<//N5
M&_QJ5B6I?;N[UNARF_ANU_1A42>[(4I>X]S*`H`4!O-V(@'PBBB(C69Z;^S#
MN6@?-LUW7<5_]PKL-;6_PFV[_=VT_P#K1*P1I_.>E=D5*:9_A_W5UT_;5_>"
M\/\`[_Q'\XI6?:G]@5UH<I?XDM_KM]879P5'B[3%`QS][]''KB7<$_B?$4(/
M(7-4$91O.-FCHK6VH1X0=HHO'Y0.*JI!#UTD"CIX&.4>E7FQT:27$X!0+S&Y
M]Z;HCS!$/&G'$`^RT]IZ3V#TD*HCS8YY\I>>DG:=[9_=-RVE;*T@ECB%BXDT
M?",E'`D%R1!8X&,X5`I2`<QU#&``#PK*K"RCA!#>*TUYB\Q-8W`&270I$TG*
M`*#&E>\\.)*M-^[,_P""[+']X4A]DL:QK<'VH[OG6U_E>_T*3])_=:K'56%;
M*I1$HBBE[M?<-8\#>/XA9^R:Y$Y?%:'PG:Q"^>LDY.4$U9-1`NIC)M?,+L+I
M](J)">`CI<=.LO&?C[HXJ+>:W,!NA:?^;QN)?98.W\JG4/E-`L=]G7MWO.).
M*)+->;$SS_+;D0`3&4;@??3/HEL].+TD9YA]3>9N/YCLWY2HZ>!`KZU.\\1V
M4>Z%0<HN7QTFU-Q<>U=S^T\GB*XY?G/;W*4.Z\$XCO18SF?L1BN\/J)WR*8M
M%C"(ZB)C-13$P_&;6M:]^^5?E]N60RW^G0ND/TF@QN/:3&6DGOJIVM=;NH11
MCS3X_6HUN5V*K-Q3<]JL+,9*L&DTS77>H*+J+AYB:X$#:*@B(!I\==)/X@O(
M#;.PM7LXM&C=&R>-SG`N+L0Z@I7$8*1]J:I-=1N,AK0K&F!K-@[_`,JVO:=R
M(G<0LH+KVQ%-0R1S>2T56+H8O4/6*&M0/Y2.6NE;OW_9Z5J37.MI?$S!IRDY
M8WN&([0*]BNFO7C[>U<]G$4]:E;MWC7A.V'";MA8;5T[2T%-=X*KW00].UR8
MY/\`LUZ"MG>2SEEH<PE@TZ-\C>!DS2?(\EO]513<;AO)!0O-.S!9O111;))H
M-TBH((@!4D2%`I"E#H``!=```K9ZVMHX8Q'&T-8T4``H`.H`8`*S$DFI7EKG
M7XE$2B*G#[T5^*/$3]0W5]H,*R[;7NN[PM)/-G^UVOU'^MJD0]VP_P``ER?W
M@7%_,M*MFO\`VWH4M>6S^'!]<^H*N9WX;@83W<USL#%4%?J"/MJ.?"'Y+A"%
M35.7Y0!4M9!HC:0#X=:U@\P]PV3<\@'1E']4*YQV^1GK([:/%]TC$@\G87&L
M.\:Q"IA2!41C@=D*80`1#<4P>BH>YGZ[>:5I-W>6D8FFAC>]K":!Q:"ZE16E
M:+?'E7&)-#LVO]FL;!\@6,8/FED.5OFUG$\+""LLSQ$L['-D!,/LRAMAS&66
M$QO5UW=`#PKHYVO^)INV_P!VVAOA%;Z;XK1*UC<<A-'$N<2?9KFPIP4^S[-@
M;`[)4OI@I2ECL'D<JHL=-Q%ND3&54,)3(G0.341$1Z"42C_DKO;GDM;BT+G%
MKH7M))P+2TC'L((]%%&8!![57SF2,BSTLG"CNCBOG!8<2^`H>TF!';_U=-*\
M?NYXK<:[.VQ^Q\9XCI^3G.2GHI13Y`X^""[C055@R-`P1S`#]#@BEO`?'78&
MM>P'1@X6<=>.1OJ"@23WBH';I_%6X/O"M]H5Y-]_?[@7/^<?^M*G2U_91]7Y
ME/?7K:4$*A5[QCAIMC_GLE?;%B+6,SK:4;)O5@#0JTG%G4A7)@$`#KY2:&M9
MGMZ7-$6]2T`\SFB_===9<M%!*T'O(P/R`*,;&C6]^:W,C$D%>+L9B[<TW5;$
M3-O"@81,U0,V9&'UQ$?4;-^HC\&M7*9K8833@%%NB2W&X-P1>*:ND>T'Y!ZE
MV@,;'M(F.813!($&,8BDW9(AX$21("9"_P````5'9-5VG1QAC0T<`NOS]X%_
M>:9/^[=I?9IJSG0_L!\.E==_F5_B5WU6^H*XEVH_W<G#S[E1O\:E8EJ7V[N]
M;H<IOX;M?T85$GNS^8GW'.9AET3("2\7A]IO$4P01,!@T]!B]0K,]-_9AW+0
M3F\W+NNX_2'YEV%%B2+*8X?6A*1K@KMA(XW8+,W!1`0.FI;!#%'H(^@:P;+E
MEIU%=C=O.V72`]O!T5?C:NNT[:O[P7A_]_XC^<4K/-3^P*ZUN4O\26_UV^L*
MZ_WP>5EV\5>"UUR&.Y9:`R'EN19VC;%PMQV+QY)$BBSUPD<!`2J%:HJ`0P=0
M,("'A6'Z3:^+,*\`M[>>&[I=(T%[XC220Y`>JM:T[:`T57WLB]N:Q>=F:KXN
M[-)SRF&\%ECG-PV:590BMQRTJ=<[9NX5(('!L4&YU%Q`0,<="Z@`B-9)K-\8
M&!K>)6J/(/EQ!K]\^XN_:CBH2/RB:TKV8&OH"D$]YBM.TK!M+A#9-CV\PM&U
MK>-=:,):\:V09,VC<K=@`%20;E*4I?D#Q^.J+;SBXN)^'%21YI;6*"SM8XP&
MM;GH`*`>[P"W%]V9_P`%V6/[PI#[)8U1[@^U'=\ZS#RO?Z%)^D_NM5CJK"ME
M4HBXI?=[VOC2R[JR%>TNE`6A94>ZD[DF5S`1)LR9(F75.83"'@4HZ!Z1Z5],
M87&@XE4M]>Q6T+I9#E8T$D]0"JX]O/'US]V#G[D;N7YO@E1P#AB1"(XT6-(`
M<Z'ML>8%&1BICH009E-[0L(=#.5`\=@U?KQXMX1$WWCQ6LVP-/DW5K[]9N!_
M\>(Y8FGK'`_T>/UCV*US6/K:-*(HP>>G^^6/_P!6.O\`W05T8_BU_P"O:;^@
M?_;4F;$^R?W_`#+2O'F=[5PMFG&;=U&2%\Y#NM1XA8&)()$KN>F5U6:J)3E2
M,8I$&B9C`*SI<Q4DR]1-4&_AM;`UC5.9=O?6\+G6EH)#-+3V(\T;F@%W`N)<
M*-&/32BH^9>Z[33K/PGG-/+0,C&+WX]`Z&CI<:`=:F\Q7%Y*")/<>6Y%L%Z3
MX%4<VE&***0\$C\XC1!10"F<*%U^E<&`-YOFE*4`"O2&\BN'!1;IT4^7/,?;
M/0.#>P=?:5E:OA7)*(E$2B*G#[T5^*/$3]0W5]H,*R[;7NN[PM)/-G^UVOU'
M^MJC!X6<V>?G;WP?(9BPW"MIWC#D2<?Q3KZ]CUI6W6=TLTDBJG$63ALLS<&(
M<F@F4`BH`'01"JZ]M8)Y,KC[04>[#WIN;;FE_>+=H?:O-/:%0'8=1!!(IW]J
MTBCF&:N=/)TL>W%6_<Y<C+D,H_613$0,[DEP\YP8B6[RFS9/UC#X$3)\559,
M=O%3H"CVV@U+<FLUH733.Q-,,3ZA\@7:!8XLB/QWCBQ<<QY2GB[(A8V&:%VA
MM,C',DV1>GP""=1Q.!)7,*@]'>NU/3K06UNR)O!C0/B%%$WR0P;*XLNV2E8V
M..M8$ZL=>(D$R"9)F=8PG.V5TUV;1'U!'H(?'TKS6>=KRIZCL?<,M]:1.=I5
MPXN8X"HC+C4QNIPH?=)H"VE,05->V]<9<1!KC[8^7M6*2Y8R*G:W[%DOA^2U
M`3%+ZH]H'R_)_P"ZW?.\O\W72M>H_,1OEFA?N9NH3BQRY?#S&F7\FOO9?YM:
M=%%=SI%MXGB9!FZUE;C;A*<R;>4/,NHT[>P[?<).9644()4G1D3`H1NCN#U]
MQBAN$.@!\8UL+Y(_*SJN]-R0W]Q$YFF6SVO>\B@>6FHC;7WJD#-2H`K7&BM&
MY-;CMX2P&KR*=RF:``````T`/`*]*0%%$"@-NE5+^U6X/I"]+B7UZA_\C7DF
MW[CO^Y/1]\?^M*G:U(^ZCZH]2GSKUM*"55T]YZQ$$KA#CQGAN0I3X^N-Y`32
MYATT:7"T!5+KIIT79AXCZ:R';TX:\@]*U<\T>@F?3(KAHJYCB/017YE#W[OO
MB0<J]QFS;G!$CZ%PE!35R2J@"!@2750"'9CT'H/G.P$/DJ[:].!#3K4)>6_0
M7S[B;(1[,37.^2@^5P78'UA"[$%U[_O!#ELGW-LH$4<$(<+;M'4HG*`AK&&]
M`C6<Z(X"`?#I*Z\/,E"]VY7$`GV6^H*XOVH3D4[<7#LZ9@.0UE1NTX"`@/53
MTA6)ZC]N[O6YG*;^&[7]&%4G]X2XS73B'G!.9L/!JEQ?R*91[V'N0$Q]C+.,
M&1(]^R44#U06$$2K`4=!,4_370:R?0;EKHLIXA:?>9/:<]KK?WMH/AS`$'^<
M!0COPKZ5Q#C5W&^YCG7$F/\`ML\<EF,FM*M/V?B+Q81JP7,RMPP"DH1W(BN9
M!LT02,('<BB"@$#0#:Z:_5QI]LQYD<N#:7,W=6I6;-'M`,1ES4.8-Z:NK0`#
MII4#IJM0>WQ%EM7N4\7K2=OV[E_;&3F<8[614`R2B[!XNS.9,3:")3&3$2ZA
MKI55J$@=;DA89RTTZ2VW3"QWT9`*]'$*WG[PQ@:\LR<#AN:R(A:??X/N1A<\
MU$-DE%W)X@K=Q&O%4R)`(F\@CGS3=/FE$?16+Z)<".;'I6X_F'VS+J.@$QC,
MZ)V;T4(/Q5KW*GWP=[BN?>W[<UX75@N1A7T??[1NVNZUIYLJ^B7@LSG.V7VM
M7#50BR7FG`IBJ!J!A`0$*RR^L8IP,W0M*^7G,G5-MS/-L`X/%"UP)&'`X$&H
MJ>E?0YK7AS0Y!,[#YH\MR/$+;S,YD(C#KEVD$8Q%G$D(Y63BHXX[DF8><&U4
M=?--J.XWC7'9>!&2QG0J[F"_<.IQLU&_!RR$A@X``4X-Z!CQZ>U6B?=D9%@[
MX;9A:-7B;ARRR"]]K1(<#&3\V(9&)N`/#<`#I6.[@^U'=\ZVH\K^&B2-/$2?
MW6JR-5A6RJ415VO>"LU7N\QQ@3@MB,3N,A\P[C;LI-HW$XKFAF+QNF5(2I]1
M37=+)[]>@D3,`^-7G1X1F,AX-6OW/S69S;0Z;!]I=.I_1!'K)'HJIG^*/':T
M>*''G%6`+)2+]3XYBD&CE^!2E.^?F#SGCM3:`:G77.=01'KUJV7$QD>7'I4Q
M;7V]#I5A':Q>ZP4[STGTG%;#5PJ_K^3G(F0ZBAP333`1.<1````#41$1]%$)
M5=7GER_><@^1-O\`&+@+%L\_9TMUBX0R#>@*;[(L1$77TCJ6D"?1',B`"(ID
M,(:^J.IO5K2CS+^36'F/N6SO]4N1;:59PO\`%H:2/.;-E!.#&T]YYQ'0.D8=
M)SF?;N=I^D1BXO''C_Z<8X5<1Q(/0/3C@<L<"L+69Q^S-%1T?=JN;,UW\+G^
MW+DO)I$%[-J(,U5R1<.F;4&4.W5+JFD305#`!C#X5!7+[S2:)/S&TW96SHF6
MVA6[I,Y8/MWMB>:UXN;4`EQ]IY%>`%<UT'ER^PM)+^^>9[^4#,]W1B/9:/HM
MZ@%.I7:8N-*(E$2B)1%3A]Z*_%'B)^H;J^T&%9=MKW7=X6DGFS_:[7ZC_6U;
MX>[L6I;%[]N:^+5O*WF5U6S-7Y<B,O`2+9%XS<I&1::E41<%,0P?*%6[77$3
MU'PQ4J>72VCFVSD>`YI<:@X@X!34X@XF<9,`RDA.84P/:N,)J4*)'\Q#0S)D
MZ43,.HD%9(@'`H^DH#H-6F6ZDD]XDJ9M'VGIFGN+K:%D9/$M:`5L+7`LA7KN
MVC1^V69OFR;QHX#:NU5(51,Y?@,4X"`A\M4E_8074+HIF-?&X4+7`$$=1!P*
M^FN+348%8X)A7$A'0O2XYAP<B.HJ^PH>.NOAMTJ&(_+-R];<^.-+M?$/3X3/
MY**X'6;LBF=U.]9':M&K%NBT9-DV;1N4"H-4B%33(4/04I```#Y*FBRL8;:(
M10M#&-%`UH``'4`,`K>YQ)J>*]BJI?*XDI85CJKG=*V?&*.5#BHHX,Q;"<R@
MCN$PF$FNNO76H^EY3[7DF,KK&W+R:DF)E2:UK6E:UQJJD7LP%,Q^-<MJ053+
MBEY6+96184UMW_:4;>MO'537/!RK)N_:"LB.Y,XI.B')N*(]!TU"OICRTU&"
MI;RQAN(\DK0]O414?*N/6-A?$&,7KZ2QQBZW["D9-(J$B^AX=A&K+HE/Y@)J
M':))B8H&ZZ".FM?3YGNXFJI;#1+.U),,;6$\<H`]2R97&KHL0W=Q^P5?\XO<
MU\X;M>\;C=$33<SLI!1CYXHFB7:0IEG*)SB!0Z``CTKE;.]HH"0K/>[>L+E^
M>6)CW=9:"?E"R-`6]`VI"QMN6Q#-;>M^'2*C$PC)!)JT;(E\"))(E*0A0]``
M&E<;G$FI5RM[:.%@8P!K1P`P`7',CXOQQF"UGEDY4L:*R':+\2F=VY,,6\@T
M.<FNTWEN2G`#!J.A@ZA7TR1S34&A5/J&F6]W$8YV![#T$`CY5PO#G&KC]Q[;
M2#3!^&K<Q6E+?UH,)$M&"CD-0-M441(!S%U#701TK[FN9)#[1JJ'1=M:?IK,
MMK$V,'\D`+RQO&[CW#3[6ZXC!]I1ESLG(O6=PM[?BD7J3P3B<5R+)H`<%-QA
M'<`ZZC0W#R*5-%^Q;:TYDGB-A8'@UKE%:]=:+,RJ22Z2B"Z95D%BB19$X`8I
MRF#00$!Z"`AXA7"KT0"*%:C$X`<(4[M/?9.*-A%NU1;V@\U^S,5Y@K[A/OVB
MCLUU'7YM57WV;+3,:+$QL+1!/XWW>/Q.O*/Y%GJ\L28LR)'P\3?V-X*](NW1
M$8"-E(IB_09:I@D/D)N4SE3]4H%]4`Z``5PLE<W@:*^WVD6MRT-F8UX'`$`T
M[JKVK%QACC&#-]'XWL.'L)A**E6DF4/'-(U)=8I=@'4(T33`Q@#IJ(:Z5^/D
M<[B:K]L-+MK5I$+&L!XT`'J7.:^%7K^3&*0ICF':4H")C?``=:(2H><C<6YG
MD_SC[>_/ZW1;SN+L?0<XA<L)[20BS%1XV</(B1;@IT6(*RNQ8H#N#U1#4`'2
MYQ7`9$Z,\2HHU3:SM0UNSU-E'1L::CJJ"6D#O./H4Q%6Q2NM,^77/WBSPCMD
M\YGG)K6&FG")U;?QVR$']QRHE\`;,4!$X%$>GFJ;$P'Q,%55M9R2GV0L/W;O
MS2]$BSW4@:3P:,7'N'SF@[5`)'9C[C??&GW5L8J;/.&7`!1T=O=F04A/]<S[
M-%005;$=%%,SI4X>J9)OM0(/Z0Y]-HW=T,%J,?:>H'@UO<.]I"R`&UL*XN^D
MX=5<*UZA@.FO3*G8W`J5X^8M2X^\8;#C,?8F0.52X)9623/<-V/":ZO)=T5(
M#'U$1VI`.TH=```Z5U;^;[8?.CF"Y^G::R&VTJM*>,`^8#I?08-/Y`_I$]&V
MG+C;N@[=MA'"#FZ32I)ZR>D^KHHO/#\1^0EO2C&:@U&$5+1AP482",D4JB1P
M#34H^6/H'30:T-VM^'CSAT34([ZQ,,-Q$<S'MF`+3V>SZ.T8*2KC=>GRL+75
M(/8M\\%1.;(AA<*69YA&8=J*MQ@%4E$5!*D5,P*`844T^HFT\0KMK\J^W^9N
MGVERW>,[9Y"YGA%I:Z@`.:N5K>)IQ[5@NMRV;G#[N*#I6>JVN5C2B)1$HBKU
M=[+ME<E^?=[X"G\"J6X2/QO%SC.X_KR57CE/.D';59+R@2:N-P;43:B(AI5]
MT?4HX&D.Z5K=SVY5:GN.>!]IEI&UP.8TXD$=!ZEMKV=.&F8^#?%B9P]G`T0:
M[WUUR\R@,*^4D&GL;U-N5/515%`0/JF.H;>GPU2:I=MFDS-6=\G=G7FAZ1]V
MN:9\Q.!J*4'8%+!5M4K)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB^/<,6><@)R$3=F8'F&;EJ1\3YZ(N$3(@H7J'4N[4*_0:%<-Q%XD9;6E01
M\:I!X+[I7/+M3R5S<0,U81-E.T,7/9)M9\9,$DHZ1:,E'JBZ*C*3;I.$G+`X
M'WI`)!V@;0#``;0RV73H+@9VFBTDTGFMK^U)7:?<P>(QA(;6H-.PXU'2,#\R
MSPKW!^]WW$5G=J<5L"GP/8LP*::UYLH]=B+5NL.@'-<%R@F0-0\1;(;M.H:5
M3_<[2#%YS%7W_P#0-\;C/AV,/@,/TJ</Z3L*=U"MS.(WN^5HQ-W)YNY^9-<<
MG<J/E0>OK.%P]5@O:C>OK(.GQQ=2`@(CJ0VQ/4/`P=*IKG6G$98Q0+,]H>7V
M".;[UJDAN)CC0DEM>TG%WR#O5CN#@H2V(>-MZVX=K;\!#(D;Q$(R;I-6C5!,
M-I$TD4"E(0A0Z`4H``58W.)-2MC((&1,#&`-:,`!@!W!?5K\7*E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(L<7I_
M36_^[GZ`?ZZ_3?/'YG_A_P#37VW@K==^\/=]/'T+F\3_`%:R_H_Z,O\`1/Z-
MX?Z/\WX*^2JZ/W5]"OQ?:41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
841*(E$2B)1$HB41*(E$2B)1$HB41?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>pic1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pic1.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``8$!`0%!`8%!08)!@4&"0L(!@8(
M"PP*"@L*"@P0#`P,#`P,$`P.#Q`/#@P3$Q04$Q,<&QL;'"`@("`@("`@("#_
MVP!#`0<'!PT,#1@0$!@:%1$5&B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("#_P``1"`"3`*D#`1$``A$!`Q$!_\0`
M'0```00#`0$``````````````@$#!`4`!@<)"/_$`$<0``$"`P,&"@@$`@H#
M``````$``@,$$04A,082(D%A<0<3,E%2@9&AL?`70E63P='3X12CTO$65!4C
M,T538G."E,)D<J+_Q``:`0`#`0$!`0```````````````0(#!`4&_\0`)!$!
M``("`04!`0`#`0````````$"`Q$2!!,4,5$A004R<4+_V@`,`P$``A$#$0`_
M`/FUSWY[M(XG6L'2P/?TCVI&+/?TCVH!<]_2/:@Q![^D>U(%SXG2/:D9<]_2
M/:@%SG](]J`7.?TCVH#*OZ1[4!E7](]J-AFGTCVI[+027](]J>RT$E_2/:GL
MM`)?TCVI[+027](]J>TZ)5_2/:4R$'1.D>U!##G](]J".->_I'M2!Z'$?G-T
MCB-:#>EJU9O,-W+=O*YW4Q`$@RH`@D!)&4(!:(#8,GLB+>MQX_"P"V!KC/N:
MHM:(]KK69=%LO@*@%@=.S3WNUA@H%E/4?(:1B^KMG`?DX&4=QA//G*>_97:J
MK+3X")-S29&9="?J#[PJC/\`2G$T.V^"_*JRZDR_XB$/7A7]RTC)66<XY:I'
MEHT%Y9%8Z&\8M<*%:,S!:GM.@EJ>RT',3V6F!J$C#4#0P$$=A\L;P@/2U;LG
MF&[ENWE8.HH2!0@Q`(`@I,00!-;G&@Q*`ZGP?\%OXKBY^UVZ)H8<O\7+FR9M
M?D-J8_KM5FV1`EX;8<)@:UMS0!0+F;;7,.2%,%I$(Y)`E&JM#9'2</K1HMHD
MQ9\,W9MR4U5$M7M_(&Q+6AN;-RK7'4\"CAUA.+3!SJWMR+*O@:M*1SX]E$S,
M`7\2[EC=SK>N6)8VQ3_/USB8E8\O%="CPS#B-Y3'"A6C(R6I[+3,U/:=%#4;
M&A`(VG0V<MN\)AZ6+H8/,1W+=O*YW4P(,20$$`02,02-O/!CDG_2UI"<CMK+
M2YT0?6?]EEFOJ&E*[E]#V;(MAL`I<%QQ#HF5Y+P@,;BM(AE*<R&K2<S!UIF:
M?#=U)&`L:;D`VZ5Y\$AM#F9)M+]:6E1+2LK>#NP[<AN,>"&3'JQV7.'S55O,
M':D6<7RGX+<H+'+XD)GXR4%_&,Y0&T+>MXEA:DPTTPR#0BA&HJD$H@M"HF16
M#3;O">TZ>E2ZG,\Q7<MV\KG=3`D8D`21E"`=A0W1(C8;15SC0=:1OHO(&Q(=
MG67+P&BAH,__`-CBN#);<NNE=0Z+*-#6`)PF5G+,!TEI")21G88)D>.93Q\\
MR"`]K2$2<`S/V\_%(S+F;?/<@V!HI1UX/.F#$:5AD&HN"6AM53EG--12HYE.
MFL6<[RPX+;(M4/C2[1+3?^(P7$_Y@KKDF/:+8M^G&,HLE+6L*8XN<A:!Y$9M
M[#UK:)WZ83&O:G0G16<MN\)I>E"[7(\Q7<MV\KF=94`02,J`)`7N14B)S**4
MANY+3GG_`&J,DZJJD?KZ4L:`&06%<#M;+*W4Y_W6L,Y6D*YINO\`(^*MF?;R
MCKYO.X)D+.OKCL2`B0!MU(`!I(@Q%M14>?!,!`NW^=B9E=#(J<.B3=]N]/1(
M<:`#UJ=+5LQ*MON4S"X:];=@R4_+O@3,)L2$_%K@HWI4QMP[+7@VGK'B/FI%
MICR&-,7,^RZ*WY?]<UZ<?^-(;RQ7G"IF]*%W.%YC.Y;MY7.ZV*0)!E0"A`;I
MP6P@ZWG/Z+/$K+/Z:XO;Z`LQU&9I7&[6PRY%_,W[K2&4K%CM''SY"MF>:XH"
MKB$VEE')V&Z(Z'`C#/BYIH78FE>:Y<MIY9(I]=$1PQ3D_L-BRLLZ2L.SI:9D
MF&".,$*)!SB_.:0;[R;PNKJ:UQ5B8<G2VMEM,2BR\>',0618)#H3A5A'G%36
MVX7:NI_4AK1RA\/$K2$#=7E=_P!V_)4`@MJ`W$ZAK[-%W<4`,1K#@!L'G[%$
MA%F(#2VMX*6EQ*MFY$%E1UU6<PN+*2=LYL0%I`-<1BLVNW(.$#@VXLFTK+AZ
M0=6-`;@1SM6U+[_)<V3'K]A]J+TWEO,5W+=O*YG4Q!B2#$`J`W7@OBAML1:Z
MVCQ66;TVP^W?+-B-XH%<CL7LC'8Z\&XK36D2MI=U:\W[?-4SE(:=&HVW]2":
MSE+)3\*TH%KR#B(\N<!CHNNHN/J,<\N<>X>ATV2LTG';U*NM?+Z8M8L?:<P"
MR!R99EQSAC=\5S=1U7/_`&GTZ>G_`,=P_P!8]_U4V%E):=FQ/Q#&E]GS+W'B
MW<@WWTYBO/Q]3?%.X]?';U/1TR?G_J'6)6,)B6AQPTLXQC79IH"*C77!?28[
M<JQ/U\Q:NIT='/V'[A:)(YE:EPO]8ZO]P^(3#,;O&_#4>?Q0"4-.=`19F%47
M*95"GC0*NO6<PVB42:D6/9I"O.EH<G:EZ[Q7F([ENWE<[J8@%2!4!@3#9<@I
MKB;>A@^NTA9Y(_&N.?U]`V+%#F-7&[-K^3>&D9M]]Z>SE<RT31'?V#Y*X92F
M0N21W=10F2O9G7$7U_[(.)4MJY*V=:$'BHD,!UV;$;B,5RYNEBT.[!UEZ3N%
M!DYDQ.R5ORT"::Z-(0W<=#`Y/&!M6EPWTJO,Q]+;N1$^O;T>JZRML4S7\M/X
MZA`@4A,!`-`'%U*G2V:R2OH*U_'SDV)R:Y@[!3J(U%4"M+2.;F/GO0DV10TU
MX4^'R1HV5"0!%8,W4-J!"MC0QUZU#6$1[*BE*)*=;7J/'>8;N6[>N=TDJ@RU
M014&(("79LTZ5G8,<>HX'J2.'?<EK39%@0W!U:CQ7%,.VLMQE9CUL5+72]E8
MH=AYQ5LI6$-PY_-?NF@XU^=I#S<#\$*/#':+^P_(J@>APPUP=KJ/DB(3-DV$
M[0VC-OZZ+1G+'D%E]*C7T@F`N#B:Z_6YMAZU(-T->?5?S(!#B-OQ^Z1D(PON
M\_,H!B/"K?V[TIA42AO:+SBH4ZBO4>2\PG<MV\K!TD2!4`008@@Q!(W2,@+=
M_J!!>[2A7=6I8Y*M<5OXZQ9,WGTI>%@Z]MEE8YT3JUI)F%G#C://Y^RI.DF%
M%!PN%?OX$IC21"?J'/CYZDTRF,B4H#<!=?X*HE)Z'%T2*ZJ5W"I50F8.U/*&
M_O\`W5$71ZJ9IW>2D3!?UX]?W"`%UXV''KN\0D9K`%PZAW_%(S46CKM=V<.M
M(X17@5`U$`J94Z8O3>4\P7<MV\K!T,2,2`5!B"`()&L;%M!TC/0XM=&M'C8D
M':<FK4:YC#G;ES6AV4MMODA,A\,'7Y^:S:+2%$U=O;3XH"?+NP(Q^5_A55"9
M26G-P\C4F27"CW7XX;_NJVB8.L<:FM::R;@&Z^U.)!\1*4.NZH[7%7M+(;ZC
M''-!ZVI`ZUXJ#N[[_@G"0%U>L#NH4C"XT9STU]J01HCP23ZP^%4E&B<T';\+
MO$I&Z8O2>4\PG<MV\KG=#*(,H094`02`P$&=9#)0&\9'6L]C1`>[3AX5UM4W
MKM6/)J=.KV+:F=#;>N:8=D2V>4FFQ!CO[%*EI"BWZ)NY^;6/%-*4R*1?A\/V
MP3!^#%U=V/4A,I<.+5M*=IT51%XW56H-0-I.)&Q,:.&+I9VJM?EW!,M'(<1H
M9NIW,^Z(*2OIN=0CN`00'U+6=$N[J_92<&'FFD,/M]T*"0!KK0]ODI$Z:O3>
M4\PG<MV\KG=)4`J#$&E(CK8)*>AM*A2R>D\DV#*;$],YNL926B0HC8C;G!.(
M9SD;K8EL%CVM>:56&7&[NGS\H;O9MJW-H;O/S7-,.^/UM,E,YU*WW"Y*"E8&
M)=C7S\0FF#D.)2B#2!%&L7[?-Z-D>X_.O)Z^;<J&A\<:_P"76W9A1!:/<=ZN
MKU_$_)4G1'17:9/=V_)`TDBE`.B+_#Q*$([B,[GUBN'FY)1K.OVW44FZBO4>
M2\Q"TY[MY6#H.L@DH&TADJ4:3R/LE-B>DS=*A2>Q5IG.1.@2.Q/3*<BR@2.Q
M5Q93=/@R.Q5%6<W2Q(%S=&YPO:46IL8\\UG:QLBU7PW\5%-(C<0N#)1[^'-R
MAO5CVEG`:74L'3ML,&:SV@^?-4CTEP(H.)W($G\XBX504'&NOQ3,XU]!YQ3(
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MM/\`V*"1XV:+A6FH[/N5$G#JR]1Y+SOAR>F;M:.+GG(G09+8JBK*;IT*3V*N
M+*;ID*4',JTSFZ5#EMBK2)LE0Y<)Z1-DED%5$)V?:P*M)V<`3+8T!3VO9CLX
MSDJ/ZT?VD,>L/FN3/A_KT>CZSA^3Z)8]NT(OI3$+SKT?18LNVZ25JLBLN-ZQ
MTZJV7,M-5(I?7!2T6D.9.;1"-'`^H2!QKQFWA,'X$2_;JWIP5C[8HJ-E^\JT
M:/-C4%QKFX;RDG17Q`<<//@IE+K"]5Y3X)9+C..];:>9-TV%+JM,YLF0X`5:
M9S9)9!3TSFQ]L)5HMG&M3T6S@3(2`,%`*@%2-K]N6,YI=/20H\7Q88U[1M7)
MFP_UZ71]9Q_)!8UN/%&YUZ\^]'T./)MN5D6QQ@`K>L9ATQ+9)>>JT*%PF-F+
M]FLI*TDPY@:T%HYQM"F-)#(U;^;!-$P=;$=\!\4)'QH.X>:))T[$O6>.T8<"
M/!>/[D'_`")KZJKE+'QZ?!#@6X,AA8H_Y$S]5/G)>-3X,<#7!L/[G'OYGZB.
MY)>+C^%]#W!Q[''OYGZB.Y8>+C^"]$'!U[('OYGZB?=L/$Q_&>B'@[]D#W\Q
M]1'=L/%Q_"^B+@[]DCW\Q]1'=L/$Q_&>B+@\]DCW\Q]1'=L/%Q_&>B/@\]DC
MW\Q]1'=L/$Q_"^B3@]]DCW\Q]1+NV'BX_C/1+P?>R1[^8^HCNV'BX_C/1+P?
M>R1[^8^HCN2/%Q_$#T$<%''&-_00$1QJ2)F;%^X1:+.8=-9X^DN%P.\'$+^S
MLC-I_P"1,_54=JK3OW^IC.#3(E@HVS:#_6C_`*TNS57DW^G1P>Y'@4%GW?ZL
M;]:78I\/R\GT0R"R3&$A^;&_6GV*?!Y>3Z+^!LE?Y'\R+^I'8I\'E9/I1D1D
MN,)+\R+^I'8J/*R?1_P;DW_)_F1?U([%4^1?ZS^#<F_Y/\R+^I'8I\'D7^KI
$:L7_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>pic2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pic2.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``8$!`0%!`8%!08)!@4&"0L(!@8(
M"PP*"@L*"@P0#`P,#`P,$`P.#Q`/#@P3$Q04$Q,<&QL;'"`@("`@("`@("#_
MVP!#`0<'!PT,#1@0$!@:%1$5&B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("#_P``1"`#"`/L#`1$``A$!`Q$!_\0`
M'``!``(#`0$!``````````````0%`@,&`0<(_\0`2!```0,#`@,%!`<$"`8`
M!P```0(#!``%$1(A!A,Q%")!46$5,G&!!R-"4F)RD20S0Z$6)3138X*BL52#
MDL'1X35SA)2RU/#_Q``4`0$`````````````````````_\0`%!$!````````
M`````````````/_:``P#`0`"$0,1`#\`_5-`H%`H%`Z4'A4D#)(`\Z#V@4"@
M4"@9%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!@\TV\TMEU(6TXDH6@]
M"E0P0:#XU+CWY%FN-G4PZ^C@6WSD15O-J<3*?>0I%O(200]RX7O=>\J@DVF3
MQBS?9D&%<)KFFYWJ7(CNM(.OD<ER'&#BV^XTZ%_9ZCH100K1QGQ\["U3+@4Q
M'NP^UIC;1<>MQ?4OM&D&*RVWC"4%"^8IOWCM027^/N+8-NN!>D/N)5;YW]'9
M9B=^8\Q*4AAW0EO&M312<8`4.]C%!?<,<1<1N_2!,MLZ2Y+AK,K0VVV$MQPT
MI/*#J%--N-G22$KYCB7.HQ05MXXPXLB\0O-QY;JKC[0F18G#ICI[.[&9@//Q
MEA[1JU..MI)/,W]W&U!76*\<67:79O:,HW!AJZ6Y]2D)45,NN,2>>A:DQHJ$
MI'=^K.2@]3N*#[10:G)"&U!*CC/3-!ZI]"?>V'G09I4E0RDY'F*#V@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4'/V"5(BW:X6&8\MYQL]MM[KA*E+B/J]W
M4=R67<I_+IH.@H*AOA/AYN]&](A@7%2E.<W4O3S%HY:G`WGEA:D#25A.<>-!
M;T"@CS(W/:4D8)/@KI_Y%!P%YN%_L4L;E4%9QR)'N_\`*>&WR-!J1Q*^L*DV
MM\I<0,K8.Y^:=]0]106W#7TG6JX246^XJ3#GKV:43]4Z?)*O`^E!VU`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%!S_%\9UIB/?HC9<FV51>Y:?><C*&F2UZY
M;[R1]Y(H+N+)8E1FI,=8<8?0EQIQ/12%#*2/B#0;20!D[`4%4OB2W*4M$(.7
M%U&RDQ$ZT@^1=V:'S504\[BZ2TRZ^X_!A-L[*:UF;)*LX"`VV6TA1.WO&@B)
MO5REE2LW=3('O,L1X[>KR"G!D@>86:"-(F-J;++Z9[B7/WB'+C%Z>(TJ7CY8
MH.5D_1Y893BY4%N\P'>9W3#E,/C0=RO0`Y@C[H/SH-=JX+6+J&7)S=]R.86)
M2#;YXQD:UH(++I&.HT'SH.VM$3B6UN\JVR>U14[KM,[*7$#_``G.]M\"10=9
M;[JS,RV4*CRT#+L5T86GU\E#U&U!-H%`H%`H*WB:\^Q.';I>>5S_`&;%>E\C
M.G7R6RO3JWQG'7%!4+^D.Q=L;AMO)[2A]IB>'`\AME3K!D:`[RRVMP(PK3J&
MV]!:V'B:T7YE3UM<6XVD(5EQIUG*'4ZFUIYJ4:DK3N"-J"TH%`H%`H%`H%`H
M%`H%`H%!QEIN;MDN$[A=AGM;D<]JM3:5)2A$1XDE#JC[@87D>>DIP*"/=+BD
MR.SRTKOEQ5G3;V@6X;9ZCZLG+HW]Y6?3%!53KJMV2F+S%722UC^K800B,P0"
M,.+[[2>O0:U#SH(4J[&%A4N>U`4D:1&MR070/NF0O4Y^F*#G+AQ9;'%$IB+E
MK'\66ZMT_P"HF@JW.(]7NP(X'EH%!I]L,%650&@?O-]Q7ZB@L8?&%P:6D-3W
M4)1[C$S]I:^6KOI^*2*#LK7])[D5L&;%>VQO'_:&R"=U(42%C'72K/YJ#Z#&
MDVV^PF)#3@.L<R+*:."/Q-JZC\23\"*#:W.D17$L7'&%;-34[-J/DL?84?T/
M\J"QH%`H%!Q\]A_C(7FW-2E1^'^S2;6IYL`E^2\CENN)SU1'SI&.J\^5!L/T
M?1<Y[:Z/ZT3=LA*??3#$/1OG;`U9\Z#9P1P0.%Q+`F=H$KE_4M,IC1T<H$:T
ML()0''-7UBDX!P-A0=10*!0*"KXHO/L/ANZ7D-<\VZ*]*#/346D%>,^&<=:#
MC9?$7%?"IM<^^7%N]1+HW([1$880P6768CDP&,H'*F\,E!YA)W!S029/TA7G
MML"WHL_9K@[.AM2X[KR%8AS6GEH=2M.VL&.H%/ACQSF@W\-\?2KLF&W$MK\]
MI+4,W.X%3+):7,;#B?JL][2E0*])VSMF@D7CC_V=?7[;[,=>C0E0$SIP<;2$
M>TWBPSI;/>7A8[WIYT%,U]-5I=3-<9M[SS4=E]^-RE)4MP1G`TI+@.`RI95E
MO4K<>1VH+)_Z38L$/M72`Y%GPEN=OB)6ATMQVH9FJDA0P%HT#1M]O:@F<%<=
MQN*#*0W&,=R*EIPX7S6U(?"M/U@"1K3H(6GP]<T'4T%%)NCUP6MBW/"/!:5H
MEW8XP#G!;CZNZI6=BL[)]3T#B;^$O-+DVR.EJ!85J>>6L[R$J.F1S'BKOEQ(
MU)W)4H"@CRIO-A%*'7+9PZE.A4A:CVV8.OO=4-GR'7QH.6N7&(1'[!9FA#A)
MV[NRCZDT'-+6ZZK*SG-!X$>%![H-!ERS0"QJ&]!@CM4=84TM2<;C'2@[?@OC
M`6O4I0U6N6M!E-@X,9\G'/3^$_;%!]C;E-.I,68$J2L:<G!0L'S\-Z#!E:[<
M^B*\HKANG3$>5N4*_NEG_P#`_+KC(6=`H.?XFGS'76.'[6YR[E<`5.R!UC1`
M<.O_`)CG0W^(Y\#07%O@1+?"8@PVPU%C(#;+8\$IV%!(H%`H%`H%!BXVVZVI
MIU(6VL%*T*&4E)V((/4&@Y-7T8\,M0)L>"VXR[(A/V^(X\\])1$:D(T*3';=
M6I+:>FR,;;=*"3"^CWAJ-";C\IUUQ#L>1VI;[ZG^9%&EG#JEE82A.0$9Q@GS
M-!BG@3A%J5$>3$4UV-+"6VDNNAI79/[.76PK0X6OL%8.*";-X9LLE^4_)C<X
MSNRF2O4K4>PN<V/T/V%G.WSH*U7!/"3'/<<CK7"D!Q!27WE,,AYP.NAMK7H9
M"W$@J*`*"VD<+</2[LY>'X3;T]^$JW.OJR=<1:M:FBGW2"?2@]L7#-JL8=["
M'BI[0E:Y#[LA6AH8;;2IY2RE"`3@"@@7>XIFHDHYBF+)#R+A+;SK>4#@QV<;
MX\%J'Y1OG`5\_ES&,O.>S[5'2'6VNXEIF,@=Q]6.BE8.A'EU\:#C;S>X\MEN
M2^V6+%&5FUVWHI]0_CO_`!\!X4'%W6\3;NI3CZMV-@T-DAI7N$#\)[I^5!`"
M#09A-!L2T3X4&Y,<GPWH-Z(A-!L$2@*@Y\*"(TVJ%+U`984-+Z/`A5!]0X&N
MO:;:Y:9"];MO">0X?M15_NE9_P`,]P^F*#M8!,J*Y`FC4"G"5?>3Z'S302;=
M)=RN%*5F7'ZJZ<QO[+@^/VO(T'MYNT:TVUZ=(RI#0[K:-UN+4=*&T#Q4M1"0
M/.@@\,6F3%:>N-R`-ZN9#LXI.0V`,-QT'[C2=O4Y/C07=`H%`H%`H%`H/"<4
M'@6DG'CY4&+S"'4X5L?!0ZT'/W*XW"TI[P+K?V,8PKT&?M>F105T:_&Y-F7:
M'!ST9$B(OW5X]Y*TG<$?J/44$BU7>2E*EV]KG,@X>M*U!+C*_$-+.V#U"3L?
M`^%!9/2+O=4]E8BOVR.O:3,>*$NA/BEE*%+[Q^^>GADT%1);8FR&(D9D&T6U
MQ*(4=M7U<A\#*<C3NEHY*M_#.]!R_%%V:FR'8?.UV6W.:K@]_P`9,'V?R-D8
M`_\`%!P%VN;]PDJ<5L@;(1X!/@!004CE*#VG6E&0Z@=2VKWP/7Q'J*#>6"E>
MGWAX+\".H(^(WH-S<<^(H)C,2@F-Q/*@D(A^E!L$0>5![V3TH(<V%E(P-U'&
M?2@ZKZ.408_$2P^YAUUKL42.!G5W>>ZM7DD!(`SYT'6\0W1B*Q<(P5-A+B,!
M\7%E@+3G(PEKWM:CD`IQOGK0+7?HU\X<MMV;>29Z_P!VN,E;@YJ?WB"C`6$G
M'>2>GQP:#7:'T\57@71>/9=G66X3`4%)<F8PY(/FEO)0U\U>5!UU`H.;O7%5
MPCWGV+9+5[6N+483):5/IC-M-+4I#0UJ2O*W%-JTIQX;D4&QGCFP<R#%FNJM
M]RG-M+[!)20XRI_9MM\IU(;6I7=2%*[QZ9H([OTG<"--J<7=D:$K=;U!#IR6
M,<XIP@ZDMZAK4-D^-!8?TOX;]IIM@GH,M>-([W+RI'-2GFXY>LM]X)U9QOB@
MSLO%-AO:WF[9*YZV`E:TE"VSH<SH<3S$IU(5I.%)R#YT%K0*#Q20I.#TH.>N
M\F7;#S7TJ<@CI*;]YO\`-Y?'IYT&+'$J$-:YB@8I]VXM#*`/\='V/S>[\*"S
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MK2I.=C0<XXU/M3TMNWN+9<F!2I$5I12$`$MN+R/<6HZFT'KU/V:#Z;89%JDV
MQB\V%CD<EM,>9`2.]H9&.44_?;&Z#XCT-!<7+B6RVZ*U)E20$R<=E;0"MUXG
M<!IM.5K)]!05N>*[VH:0>'[6>I.ERX.#X=YIC_4KX4&B;P7<V;@W<>'+M[/F
M&(F!+5,:5/#S3:U+:6=3C2^:VIU>%%1!S@CI00G/HWF*66?;3CT"7V%=W[2T
M')4AVWE)2M+X4@(YO+3K[A_#B@D(^CMM,.+&[<?V:#<H&KEC?VFM*RO&=M&C
MIXT%7$^B!B-=6I2)J"RA;<C*F"J0F2U&3'"VW%.%I(R@+'U14#MG%!9<$?1^
M_P`.7&1<)%Q$Z1(B,PW%<M:2KD+6H.K6XZ^I2U\SO;@>0%!V=`H%`(!&#N#0
M<U<.#P'%2K*]V%]6ZHYWCK/Y1NC/X?TH.;$BZV1_2M'LU2S^X<&N`ZOS04XY
M:C^`CU2:"S<XLLKR![4;5;):=DR5'+>3]R2C;'_S--!C'X=MJKY'OLM[M[L?
M/8R=&&\IW5W0"2<C!H,>))-T<D/383")3,-"TMQ5J<0'G-`<?W01_#P$YVV(
M\:#@^(>()\]QF=-T)>+.B)%9_=,-JZX\U*\Z#GD-9%!N;8H)C4:@A\0Q;RW"
M[3;$A3C:5A8Q]9H6G"M/GMX?.@Z*SLA^#'?3T<;0H?-(S07+,3TZ=:"2B)Y#
MK0;TQ:#:(@\:#+L@\!0:W88*2#^M!63+<[(2VRRWS),G9IKID>*CY`#<F@H.
M(^&+W86VIA;:E1=2=3D?(4VL'(&%=1ML10=4NW(;N[JG%EXW,B5SU`#7SALG
M;;ZO3H'_`+H-T%#W#]Q,QM13`D#EW`#[*?LO#KNWG],T'1V&PVZSW-U*$&1(
ME(YK=S?/,D+QLM"G/(9"@$X&_3:@Z*@4"@4"@4"@4"@4"@P>99>;4T\A+C2]
ME(6`I)'J#0<C??H^8?96JTN=E<(_LR\J95Z#Q1\MO2@YKZ.T/QK]+X<N+2F@
M&U.L,G^$MM2>8E/AH5K2M/AUQUH.R3/B>W?920G]A)=4$Y/<5'.2OPSE73RH
M/CTAD*C13^`D?#.U!J1'5GIGSH)K+"*">S%&1C]*"R8A^(\*"RBPPE`2!@#I
M0340_'QH)*(PH-HCT'H9H,N50>!@%6_3QH'#\9"W9<_&>\8T?T0CW\?%>WRH
M)5YA=LL\V+C*EM**?S`9'\Q0<DEY3_#]CFI4>='0^AU'^$R0K5\B$CYT'6H;
M9D,@X"D+&?D10:H:EL0%L')=L;J7&CU*HJAT^394C_+0=1UH%`H%`H%`H%!I
M[9#Y':.>WV?..=J&C.=/O=/>VH-U`H,4N(7G2H*TG2K!S@^1H,J#G[A:FAQA
M:KLC"7%-OQ7A]_N:T'_+I505EK1RY$U'*+*PY-[IW[I'<[W0[ZCMT\=Z#X_<
MTS8-TLTCM:W(%R"(CD)>"AI?+)0ML^\,J1O\:"_;C'_-03HT56H>O4?"@LFX
M@T]*"PC0P#CW5_[T%DRT@[=#XCQH)2&10;0R*#/E4'O*H/.70:I*@S'=<\$)
M)/RH)-F8Y%EAM_:Y06O\R^^?YF@DI&5`?>!!H/DMGE.M76=9I3F(Q0Z8H_P^
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M'[Q2<K26EN-K!!]*"!<>+X?:;6_(@W"$&I7?[1#>QA;+C>`6TN`G*AMF@J;7
MQ1PLWQ#.YEP:CLR)2G$]H/(V<8(5LYIZK3Z4'`\6L:^%FI4-29+MJ>;DI#*@
MLE$9[*L:<]6\T%];7H<QAN5$=2_%>&MIY!RE0]#06\:/OZ#I\Z"P;9\//:@G
M\@:!D>(Q^M!);8.5%.%#P"]^GK0;$Z@K2`4CQ&VQ]#0;0R1OGXI2?^]!L2<;
M']?_`#09T'F*"#>0?94O'7E+Q_TF@GP70Y;8BT]%,MD?]`H-@]Y'QH/C\OMC
MG$CST,-)Y`EN*>4'24MJ?&00A0!"BG_>@[>Q,<5^S(W+D6]M)1D)4P^HC)SU
M#P!H+!+7%WM"*GM=NYFATI/9G]@-&=N?ZB@V6='&#EM8<8F6X-+!*`8SYV)/
MCSQ03>1QO_QMM_\`M7__`-B@I>-K/QE<^"[[;U.19;TN$XU%9BLK:<+JO=[S
MKJT?K00;UPC?;>N/?VYTZ_75J3!$I*0PRY[/CNJ6XTTVT&$JR7"I04=\4''2
MHG%,J[2(3\"Z&]/P9LJT-(E!(A/OW1\PWW]+H1W6RG?O82"G%!V_"5CXDC\8
M.S[FTLLZ+HVF0M04,/7!#K`2,DA);22D>`H.^H%`H%`H%`H*GB@*%E=D)&50
MU-RQ_P#3N)=5_I2:#G>,8D.<_*M\E2647%J,J/)!U;LN'8H\1A:LGIB@Y&XV
M=N!#N.F$PQ>;:TXD.--I&?JB4+2K`.%;4$?@:!%B<*VIJ*GZE49MW/7*W4ZU
MJ/Q4HF@ZN,W_`#H)[3>%9QG`V'J:":AI?=*CT/0=*"0R.X!Y;4&:T9&?$4&2
M3TSOGHJ@]4-J`!^E`-!K>2%M+0>BAC%!$X9=/LEN.K]Y#4J,K_(>Z?FG!H)G
M;8W9G9+;J'&HX67%H4%`*;!U))'0C&XH/G?#T9UFW)O(]ZXB2E:R=LLJ*FTC
MT4-6?44'?6E!1!81Y-I'\J`Y+#,N=-_AVR&4_P#,=^LP/72A/ZT%G8(IB6.!
M&5[[4=M*_P`P2,_SH)]`H%!YH1KUX&O&-7CCRH/:!0*!0*!0*!08.M(=:6TL
M90XDI4/0[&@XFYE2N&8$HM!4V`LPI*@LI4D-Y:=`2/?U:/=^=!"XF?BMOIN$
M]Q,>+)@*[8\X=*4JC$I<*B?S4',?1R7%\%V<G.`QI;SL2V%*#9^:,&@[*,F@
ML6$[Y]1C_:@F:1IWH/4I(V^V/YT&Q.XS08Z!DCIG<4&0_GXT"@&@U+.*"C,E
M-JO*Y*U:8,W2B03T0X-FW#Y`^ZKY4%)](TJS6J"N<P.1=YOU9[.K1SVL=_M"
M-T.IQL-0SGH:"%,D2H=OM5IGMH8C0FPZ'8^M:-+_`-IY'>=;4D:OO)\<B@[U
MN?%1;A,96),<@<A3)"PZ3LE*",@E1P*#5/C.H@1;2M0,VX.AZ>4^:E=[Y`[#
MT30=4``,#I0*!0*!0*!0*!0*!0*!0*#G9+3:;I<+7I&JZ,&9$"SI27VP&G,$
M;@CZM6V_C0<O<"[)MCB)S&7H#@?D,/:5ZVB`W()3]WO)5N/.@S*$I6-&.60"
MC'3'AB@FQ@-L[T%LRG:@EZ=@:#U2`H8_2@\0G!./'_>@R.*#'&V?&@4'A-!H
M=.U!S]S6DMN#3S5.*Y>GP45'2$[[>-!P'L=N3<(+;,=*1<G^1'<U:@>6L)64
MC?"1G;PH.XAI[?Q$[-.>6T\LL'S0T.4UC],T$M%C8>5(OD%_V,ADZF7FD!3,
MA:?>=<CGN+&^E*AA9\#TH,H-]>AW14KB6,8VC==P9!<BI4I`"$N=51]*"<A>
M1E7O4'<,O,OM)>96EUIP:D.((4D@^((V-!GD9QXT"@4"@4"@4"@4"@4"@4%#
MQ?$>[&Q=8J<S;.Z)30^\C!2\W\%MJ-!3WB/&<N%NXBAZ'(\[ZIW("2H.HT\M
M2ADGF8TZ5;!7C05<=ODNKMJU:U,`.PG3_%C+]P_$=#ZB@L(QWH+:,H'%!8)&
M:#W308::`10,4'F*#6LT$*0YB@J8)=>XA@([/K8:=RX<:@DJ;6I"E`=-T[*\
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MDN(6VX^RVXMMU/+<25I!(6C?2H9W&=J"50*!0*!0*!0*!0>$`@@C(.Q%!QK#
M+-MFRN')W_PFX?V-1^PISH,^1.P\E?F%!`?M,WE)AKPW=H"]4%PY">^<!"E=
M"B0$]?!SJ.E!LAR$2FN>@%"TDHDL*V4VX-E)4/C06<9P;4%DT[02$J%!Z0*#
M$@4&LT&"E8H(SKE!57!]0&$G!5X^5!KX<D%/$KJM6EIB%^U'P*E+'+'QV507
MM[<%Q@N6[G/1S,`0E<8@.@9&3D]`1M087-N!$@L6.(VAM@-_6LI`PF,-BG_F
MGN^N]!0<(:#=H\":ZI4>,A;O#_,_C-(.A65'WE1LZ1YI(50?0*!0*!0*!0*!
M0*!0*!0*!0*!05?$%F1=(11@%YO):U>ZK/5"O17\C@^%!QDZ]QUQ1;)^MZ^H
M3RX/+052WFE'"VEI04E"QIW4K"3[PH(;2[O*E.S&TM1;PVI3'LY;@4Y*#&RT
M/+&$<\`ITJ2,'IGR"TM5XAW%"E1B6Y#1TR8;G==;6.H4D[B@M&I=!+1*%!O3
M(%!Z7A08%T>=!I6[01'G*#GKQ=&XXRKO'(2RT.KCJCA*1\Z"WLEK<MC)5)(D
M7&2OFR-.Z>9C"$)\PV*"XUB%I.CFW%X?5->0\7%G[*1__;F@J9#+DJ:+6RX7
M)4L\R?+Z$-C92O0`=U`_]T%[?K"F?;6V8BA&FP2EZUR,?N7FQA.WB@CNJ'BD
MF@V</7D7:W!];?9YC2BQ/B$Y+,A'OH/F/%)\4D'QH+.@4"@4"@4"@4"@4%!Q
MUQ,YPUPS(N[;;3BVG([0$A9:9':)"&-;BP%$)1S-1V\*"@LOTIQ747`W+L[J
M(;L=B/,M#CDUB2_)UXCM=Q!+S?+RM(R`""2*"0KZ4K0]*0S!:<<9<BIE"<ZA
MQ+*5&8(:V',)*DNI<R"".M!-8^DKA=]<A*%2<1VWW$N&*_I>$1WD2!'.GZTM
MND)(3YT&Z-Q]8)%M>FM]HU,2>Q.0BPYVKM.@.!KE8SDH4%#PQXT&/)XLO9!?
M6>'[:=^0T4N3UCR6YWFV?@C4?Q"@USN"K='B*]E1@"=Y+.HE;Y&X675'7S4G
M=*RK_P!!2J$*3R_:Y4D-K^KO"$@.)4D:0B:@@^[][IYXH-'$=B+?]:3G%(>;
M`[/?X'><Y?ASTGNK2/QGX*H-"9]ZBM:YC(N$<#/;X0.0GP+K!^L1^A'K0287
M$,.0,LO!?IG>@LF[@DCK0;O:`\Z#SM@/C08KF(`R5`#S-!1W'B2/I=1#0[.=
M;22X(Z=03\3T^7C0;N&+%+,M-UNS0[:4XA0#WN1JZK<_Q,>'V?C0=,T74OK2
MP`[-&RE*W:CY^^1[SA^Z/Y4&F;(9MZ"E&J1/DD)SU==<\!Z>@Z`4%K8;.8#*
MW7R%SY/>DN#IM[J$_A3G_O06E!S%^0JQ7/\`I-'23$6$LW]E/BRG9$H#Q4Q]
MKS1G[HH.F2I*DA22%)4,I4-P0:#V@4"@4"@4"@4"@K.(K#&OMM]GR5J0USX\
MC*,9U17T/I&^1@J;`/I04%Y^C&SW*1,=2\MA$J0Q/[)H:=C(FL(4T7PRXE23
MS6U:7`=C@'96]!BW]%]N0W&;3->2AIGDOI0VPVES]K3-2K2VA*4:7$X`2/=V
M]:#V;]%]JE6QN!VV4TEEN<TAU!2%8N$E,IS5MN`IO3CQ3D&@L^$.#H?##,YN
M,[S/:$CM;R0VTRVE?*0SAIME*$I3AH;4'04"@JKK8D2EF3&4&)N,%6.XX!T#
M@_V4-Q_*@YEIF;;9"F8BS;I#F5*@.#F17/,I3L#GQ*"#YB@U2FK<^>;<;<[;
MY2$GE38!6ZRE:NKH;;T.)5M]WIXT$.19XUU64Q3$O"\91++@8D_B0YHTNZON
M['UH(@X2O;2-;3=PA)VP%%F6G?Q(RTM('CF@T*9O"-(3<V7`OW-45\$^@TZ@
M3M09,PKO*T<NY:R[D(1&BN*)*>HRLMI!^)H/3:K%'D--<0W%3$ETIY<:8\C6
MXI71*8\=6K/H5&@[N%;+#"@"4EU"8J<\MQ&$MCP^KT@#?S2,F@R',>20TDP(
M./>]U]P?[MC_`%?"@B.W-#93;;4QS7P.XPWL$C[RCT2/4_SH+*S6'LCAFS%B
M1<G!@N?8;!^PV#X>9ZG^5!;T"@\4E*DE*AJ2K8@]"*#A[A)O'"/#/$;$5)7%
MM=OD3[#+6-:&TH;4H17//E+'<\T;>%!K/TAS%W!J+V!Y$=FX,VYV8@M+[1(7
M#[4IM#1.I*=)'>\]J"VX%XX:XKB27DQ>QN1E)2XPIU#CB=:<Z74#2MI:>BDJ
M3\":#IZ!0*!0*!0*!0*!0*!0*!0*#3*B1I;19DM)=;/V5#/S'D:"H<L,R/DP
MGP\WX1Y.<CT2Z,G_`*@:"KFVN*^?ZQMJD+'\0MAY/R6C5CYXH*Y=HB)6>R7!
MR.OR;DNM'_IUC_:@A2XMV;5RV[Q/<=.Z66I#KBS\DDG]:"ND<-3GD*7>+G*:
M8QE3/:7'5D>.HZBVG_501;3PS;2[HMMO1$97LN8H?6+SXE1[ROUQ0=G;85KM
M33;(6J5*2/J&D@N+'Y&T^[\:"T3:KO<0.U+[!&_ND$*>(]3NE'RS074"W0H#
M/*B-!M/51ZJ4?-2CNH_&@DT"@4"@C7*W0[G;I-NFM\V',:6Q):R1J;<3I4G(
MP=P:"`>$>'CUB`_M0GG*E?V@,]G"^O\`==W'2@]L/"MEL2GUV]MSFR`VAUY]
MYV0YRV<AIO6\I:@AL*.E.<#-!;T"@4"@4"@4"@4"@4"@4"@4"@4'BE8H*Z;J
M?[I/U?W4@?S4=_TH*_L[$5DHCM):0=R$C2"?,XW-!336(^>8_P![&XU]/DGI
M^M!NA6FY7(@H_9H?]\H;D?@3X_$[?&@ZR!;8D!GE1D:1]I9W4H^:CXT$F@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4&IY20-]Z"$X5'T%!J[-(>_=H_
MYB^G_DT&V/882'0^\.T/CHI?NC\J>@H+*@4"@4"@4"@4"@4"@4"@4"@4"@4"
I@4"@4"@4"@4"@4'FD>5`T(\A0>T"@4"@4"@4"@4"@4"@4"@4"@4'_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>6
<FILENAME>psivida_ex99-2.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><img src="logo.jpg"></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td valign="middle" width="28%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ASX/MEDIA
                  RELEASE </strong></font></div>
              </td>
              <td valign="middle" width="28%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              </td>
              <td valign="middle" width="28%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>21
                  February
                  2006</strong></font></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div>&#160;</div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>pSivida:
        Diabetic Macular Edema trial with Retisert</strong></font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><sup><strong>TM</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong><em>&#160;</em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong><em>Positive
        Results </em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong><em>for
        pSivida</em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <div>
          <hr style="COLOR: #000000" align="left" noshade size="1" width="100%">
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Global
        bio-nanotech company pSivida Limited </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(NASDAQ:PSDV,
        ASX:PSD, Xetra:PSI)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        today
        announced the publication of preliminary three year follow-up data from
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bausch
        and Lomb</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8217;s
        multi-center, randomized, controlled clinical trial of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>&#8482;</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        for the
        treatment of diabetic macular edema </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(DME).
        Global eye health company, Bausch and Lomb (NYSE: BOL), exclusive licensee
        of</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>&#8482;</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        from
        pSivida, conducted the study</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        in
        hospitals in the United States in which 197 patients were randomised to receive
        either standard of care (repeat laser or observation) or a Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>&#8482;</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        implant.
        The study concluded that significantly more patients receiving a
        Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>&#8482;</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        implant
        had improved visual acuity (of three or more lines on an eye chart) than
        those
        receiving standard of care. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">DME,
        a
        common complication of Diabetic Retinopathy (DR), is the leading cause of
        vision
        loss in people under the age of 65 in the United States with an estimated
        500,000 treatable cases. DME is characterized by swelling of the retina and
        loss
        of vision. Currently the only FDA approved treatment is laser therapy in
        which
        holes are burned into the macula with a laser. This treatment is often
        ineffective or generally provides only temporary benefit. There are no approved
        drug therapies for the treatment of either DME or DR. Retisert&#8482; for DME is
        surgically implanted into the eye and releases a constant amount of the drug,
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">fluocinolone
        acetonide</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
        Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        is FDA
        approved for the treatment of posterior uveitis with a duration of 30 months
        and
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">is
        licensed to Bausch &amp; Lomb and co-promoted by Novartis.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div align="center">
        <table bgcolor="#ffffff" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="#ffffff">
              <td valign="bottom" width="30%" align="center">
                <div><em><font size="2"><img src="pic1.jpg"></font></em></div>
                <div><em><font size="2">Injectable Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 7pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font></em></div>
              </td>
              <td width="40%"><font size="2">Medidur<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>&#8482;</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                is
                pSivida&#8217;s next generation product. It is a tiny, injectable device that
                can release the same drug as Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
                Unlike Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
                which is surgically implanted, Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                is
                injected into the eye during </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">an
                office visit. Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                is
                in Phase III clinical trials in DME </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">in
                collaboration with Alimera Sciences Inc.,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                a
                specialty pharmaceutical company focused on the ophthalmic
                industry.</font></font></td>
              <td valign="bottom" width="30%" align="center">
                <div><em><font size="2"><img src="pic3.jpg"></font></em></div>
                <div><em><font size="2">Surgically implantable Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 7pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font></em></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;As
        Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        and
        Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        can
        deliver</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        the same
        drug, at a similar rate, to the back of the eye, we hope the Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        trials
        in DME show a very similar improvement in visual acuity to that shown in
        the
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        DME
        trial. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        differs
        from Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        in that
        it is a smaller device that can be inserted without the need for
        surgery,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
        said Mr
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Gavin
        Rezos, CEO of pSivida Limited. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">R</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">esults
        of
        the Bausch &amp; Lomb study has shown that a statistically significant number of
        eyes </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">treated
        with Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>&#8482;</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        had an
        improvement of visual acuity of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">three
        or
        more lines on an eye chart </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">compared
        to eyes receiving standard of care (28% versus 15%, p&lt;0.05)</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
        Additionally, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a
        statistically significant number of eyes </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">treated
        with Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>&#8482;</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        showed
        an improvement in their diabetic retinopathy severity score, a measure of
        the
        severity of their disease</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        (13%
        versus 4% p&lt;0.001).</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        More
        eyes receiving Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        also
        showed a reduction in their edema and there </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">was
        also
        no evidence of edema in 58% of eyes receiving the implant versus 30% of eyes
        receiving standard of care (p&lt;0.001).</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Side-effects
        of Retisert&#8482; in patients with DME were similar to those reported in patients
        with uveitis for which Retisert&#8482; is approved. Of the patients with DME receiving
        Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>&#8482;</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
        at
        three years 33% required an operation to relieve elevated intraocular pressure
        (IOP) and 95% required cataract surgery. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cataract
        surgery is a relatively uncomplicated and established procedure with a high
        success rate. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        abstract (#5442) detailing the DME data is available on the website of the
        Association for Research in Vision and Ophthalmology </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.arvo.org</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
        The
        three year uveitis data is available at the same website (abstract </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">#</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1523).
        Fuller data will be presented at the ARVO conference in May 2006.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        receives royalties from sales of Retisert&#8482; for chronic non-infectious posterior
        segment</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        uveitis,
        a sight threatening condition that affects an estimated 175,000 people in
        the
        United States and an estimated 800,000 people worldwide. The product is
        presently priced at US$18,250 and is approved as a 30 month treatment. Covered
        in the United States by Medicare and Medicaid, Retisert&#8482; is co-marketed in the
        United States by Bausch &amp; Lomb and </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Novartis.
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        the
        event that Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        is
        approved for DME and Bausch &amp; Lomb decide to market Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        for DME,
        then pSivida will receive royalty payments from Bausch &amp; Lomb for
        Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        sales
        for DME.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>-ENDS-</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div align="left">
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="justify" valign="top" width="30%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                  Limited</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brian
                  Leedman</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
                  Relations</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                  Limited</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  + 61 8 9226 5099</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">brianl@psivida.com</font></div>
              </td>
              <td align="justify" valign="top" width="40%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>US
                  Public Relations</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverly
                  Jedynak</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
                  E. Janis &amp; Company, Inc</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  +1 (312) 943 1100 ext. 12</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</font></div>
              </td>
              <td align="justify" valign="top" width="30%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UK
                  &amp; Europe Public</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Relations</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                  Swallow / Helena Podd</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Citigate
                  Dewe Rogerson</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  +44 (0)20 7638 9571</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">mark.swallow@citigatedr.co.uk</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTES
        TO EDITORS: </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>What
        is Diabetic Retinopathy?</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        Diabetic
        Retinopathy is a complication of diabetes and a leading cause of blindness.
        It
        occurs when diabetes damages the tiny blood vessels inside the retina, the
        light-sensitive tissue at the back of the eye. A healthy retina is necessary
        for
        good vision. Diabetic Retinopathy usually affects both eyes.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div align="center">
        <table bgcolor="#ffffff" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="#ffffff">
              <td width="70%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>What
                  is Diabetic Macular Edema?</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  Diabetic Macular Edema, a subset of diabetic retinopathy, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">is
                  the leading cause of vision loss for Americans under the age of
                  65.
                  Retinal blood vessels in diabetic&#8217;s eyes deteriorate and leak, causing the
                  retina to swell. A minority of cases receive long-term benefit
                  from laser
                  treatment.</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>What
                  is Uveitis? </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An
                  autoimmune condition, uveitis manifests itself as an inflammation
                  inside
                  the eye, that can lead to sudden or gradual vision loss. </font></div>
              </td>
              <td width="30%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><img src="pic2.jpg"></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
        <div>&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        is a global bio-nanotech company committed to the biomedical sector and the
        development of drug delivery products. Retisert&#8482; is FDA approved for the
        treatment of uveitis. Vitrasert&#174; is FDA approved for the treatment of
        AIDS-related CMV Retinitis. The technologies underlying both of these products
        are licensed to Bausch &amp; Lomb. The technology underlying Medidur&#8482;, a
        treatment for diabetic macular edema, is licensed to Alimera Sciences and
        is in
        Phase III clinical trials.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        owns the rights to develop and commercialise a modified form of silicon
        (porosified or nano-structrured silicon) known as BioSilicon&#8482;, which has
        applications in drug delivery, wound healing, orthopaedics, and tissue
        engineering. pSivida&#8217;s subsidiary, AION Diagnostics Limited is developing
        diagnostic products and the subsidiary pSiNutria is developing food technology
        products both using BioSilicon&#8482;. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida&#8217;s
        intellectual property portfolio consists of 70 patent families, 74 granted
        patents and over 290 patent applications.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        conducts its operations from offices and facilities near Boston in
        Massachusetts, Malvern in the United Kingdom, Perth in Western Australia
        and
        Singapore. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        is listed on NASDAQ (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSDV</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
        the
        Australian Stock Exchange (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
        and in
        Germany on the Frankfurt Stock Exchange on the XETRA system (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>German</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Symbol:
        PSI. Securities Code (WKN) 358705</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
        pSivida is a founding member of the NASDAQ Health Care Index and the Merrill
        Lynch Nanotechnology Index.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company's largest shareholder and a strategic partner is QinetiQ, a leading
        international defence, security and technology company, formed in July 2001
        from
        the UK Government's Defence Evaluation &amp; Research Agency
        (DERA).&#160;QinetiQ was instrumental in discovering BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 7pt; FONT-FAMILY: Arial, sans-serif"><sup>(TM)</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        and
        pSivida enjoys a strong relationship with it having access to its cutting
        edge
        research and development facilities. For more information visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.QinetiQ.com</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
        more
        information, visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.psivida.com</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
        document contains forward-looking statements that involve risks and
        uncertainties.&#160; The statements are indicated by the use of words such
        as
        "believes", "expects", "anticipates" and similar words and phrases.&#160;
        Although we believe that the expectations reflected in such forward-looking
        statements are reasonable at this time, we can give no assurance that such
        expectations will prove to be correct. Given these uncertainties, readers
        are
        cautioned not to place undue reliance on such forward-looking statements.
        Actual
        results could differ materially from those anticipated in these forward-looking
        statements due to many important factors including: the failure of the results
        of the Retisert for DME trial to be a good indicator </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
        the
        results of pSivida&#8217;s ongoing Phase III</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        Medidur&#8482;
        for DME trial; failure of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
        Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        trials
        in DME to show a very similar improvement in visual acuity and diabetic
        retinopathy severity score as Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        for
        DME</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">;
        inability to recruit patients for the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Phase
        III</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        Medidur&#8482;
        for DME trial; our failure to develop applications for BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 7pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        due to
        regulatory, scientific or other issues, our inability to successfully integrate
        CDS&#8217; operations and employees; the failure of the CDS&#8217; products to achieve
        expected revenues and the combined entity&#8217;s inability to develop existing or
        proposed products; the failure of the Bausch &amp; Lomb/Novartis co-promotion
        arrangement to provide faster royalty growth. Other reasons are contained
        in
        cautionary statements in the Registration Statement on Form 20-F filed with
        the
        U.S. Securities and Exchange Commission, including, without limitation, under
        Item 3.D, "Risk Factors" therein. We do not undertake to update any oral
        or
        written forward-looking statements that may be made by or on behalf of
        pSivida.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>pic3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pic3.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``8$!`0%!`8%!08)!@4&"0L(!@8(
M"PP*"@L*"@P0#`P,#`P,$`P.#Q`/#@P3$Q04$Q,<&QL;'"`@("`@("`@("#_
MVP!#`0<'!PT,#1@0$!@:%1$5&B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("#_P``1"`"*`*D#`1$``A$!`Q$!_\0`
M'0```@("`P$```````````````0!`P()!08(!__$`#P0``$#`@,#"0<#`P0#
M``````$``@,$$04A,0<20084%R)15F&5TQ-"<8&1L?`RH<$C)%(5@I3"T?'R
M_\0`&@$``P$!`0$```````````````$"`P0%!O_$`"81`0`#``("`@$$`P$`
M```````!`A$#$@0Q(4%1!2(R<1-"@M'_V@`,`P$``A$#$0`_`/,*02D`@!`"
M0"8"0"`$&E`"`$`("4`60!9`"`A,!`"""`VBJ@U<!2$H`0`D`@"R`FR`$&$!
M*`+("4`6"#9!CCHTGX!`7LPZO?\`HII#_M*GM"NDA^'5\8Z]-(T=I:4=H'22
MQ%CGJJ0$!"`$`)DVB*@U<J0$`(`2`0$H-*`$&LAADFD;'&W?>[(`9I2,<M2\
MC>4U4_<AP^4\+D6'[K.>:L?;6O!>?IVC#-BO*FJL9RRG:?F5C;S*NFG@7GV[
M9ANPC#V6Y[4/F=Q`R'[+GMYL_3KI^FU^W:*#9-R5I;;M('N[2L;>1>717P^.
M/IS<'(7`8QU:1@^2R_R2VCAK'T=9R8PQF3:9@^279K%8$_)/"I&]>!GT2[24
MQ#JG*#91@5=&[<B#).!"WIY%H<W)XE+/C?*W9YB>!O<]C3+3CCQ"]#B\B+/)
M\CPYHZBNEQ!`"8;0U1-7*D!(!`"`FR#.8?A6(XA((Z.G?.X_XC+ZJ9M$>U5I
M,^G=,(V-\I:S==4N92QG6^97-?S*QZ=E/!O/OX=ZP?8CR?I@'UKW53QK?]/T
M7+;R[3Z=U/T^L>_EW+#>1N`48'-:*-EO>L+KGM>TNNO#6OTYNGHHFFP:!\`H
M:8>;`-RS6I)6BA+<R+!"NS)D3![N2:ES(V:G())E,OLF-N,T""KI6Y@I-,)S
M/"98XC%L/IZZ!T4K`YI"J)Q-JZ\_;0.1S\'K'5$+?[=YS`X>*]7Q^;L\'R_'
MZSL>G35U.$)AM"5$U<J`$`(-RN$<F\8Q:4,HZ=S@??.35G?DBOMKQ\5K>GU'
MDQL8I(PR?&7^W?K[%N35P\GES]/2XO`C_9])PS`\/H8VQTL#(F#+JA<=K3/M
MZ5.&*^G*LBOH,E+:*F&07T0%T3,[_LDFQZ)C.R[3VY)LY7-W&G>`ZIX]B"6[
MC=#QT!0E4=P.RR;:Z%:J=*T$%)12HJ':!#2L%C-<>*#+R2V"9%G27TT0)=8Y
M98;#B&&S1.;=UC9:\5LER\].T/.U=2NI:J6!WN.LO:B=A\[:,DNFEM"5DU<J
M`8HJ&JK:AL%-&9)'<`E,XNM)F?A]+Y,;*F[\<^).WW:F/@%Q<GE?AZ/#X7Y?
M5,-PFDHHF1P1AC1V!<,VUZE..(<FVV0"AM6#4;3EV(/3;!EPOP2+5C#<@#0\
M?_?!!&*>.[NUIXG(??BFFUCK&-#]W@[4Z7(_E-EV2^(A[L^IH[[CY62PXNH>
M\@;I.GO?PDI7[7(]HX^"1X6E?;Y(5!9TOU\4&I>X`)GI&68`E`*B=N\4'+C\
M3EN+*H9R^#\N:818T\M]Y>OX\_M?/^77+NNK=RMH2LFMODYR)Q;&I6[K#%3\
M9'=G@N;DYHJZ.+QYM_3[!R;Y%X=@L+1%'O3>](=5Y_)S39[/!X]:NR0-#0N=
MTP:;,2$VD0OIW7XH5)Z*3A]4DL]^^GZ>W^4`Q"6W/&_#['+6VJ$VDZZJ:`&D
MWN=UQS)OPMF$,H@P]X-P..A+K.N/&YSLC8],X2]VY$&R9N`TT\=!:_Q*K"B?
MGX(SR&][\-?OIP^"ET5+OGW;D%2HO[6]RD)4RSMN039))22=_`JEDJN86014
MO*I6D*V:RJ$6E\<Y?6.)W7I^-Z>%YO\`)U5=+B;0E9/*U%34U-&(X6AK0.`7
M@3.OH:U,N>-W(\$FRF&33LXE/#U=[47LAI4Q%..&B2C39S;7(D?R@EL4UV6/
MY<:?6R`8CG=Q.7$?F21'&S0.&Z<PX=F8\>!5(^8%-/\`WQ8]W6F;D2;_`-2,
M%S2,W?K9O?,!<'E3TO7E_P"9_J?_`"4VCX7SU+-W4V'#LXY?_*[Q6I">J!/9
MXWU^:EK$%)9O'(I*@FZJ<SQ'\)"51GO=!*#4D.-RGB9)35&_DJPU3IK"W%`<
M9B-3N@W5UAE:7R'EA4";$C;@O3X(^'A^7/[G`+H<K:$J)Y,;4KP<?20R,I+3
MGE9/%L(*FXN@8M9/US]4FIRGDSN?S\LE)R8=+U3^?FJDX9P3@Y.XH$K^=AH^
M_P`D$L;6D^'PU_9,8JK)YC%[2G?_`%X")87:@.8=X7.@S':IY..+UFL_9?VD
MXI'/>6F!9!)UHXCJ`>!L7#+Y+/@B\4B+_P`H5%?S[5OK+@W_`&6IX7DJ;\4$
M7?-G;M06JWS;L?\`X0@C-5N589?VAN,\E2.S":H:!>Z,+LZ]C6)-9$XWT6M*
ML.2[Y5B-09ZM[SVKTZQD/$Y+;)94S;059/'393DO$?2FF2NW#;6R#*P2^*&B
M]TV[NNOD<E.*@U#57;JIDU_.TL.(1SMS,M2$\-FVJ>[,E&!9SC*WU_.S[H&L
MA/E;4C,97/RX!-,J34V;F;^'5_ZV*4PI5+7=;(HP*'5ECK=/$RK?6`D(Q(?4
M@(QGI"HJ;G(JL+57.+#)/")5E:&M-RKBJ+6=%Y2XSOM,;"NOBH\_R.5U5=3S
MD)AM!5$\9[]EXCZ2##)=/L@RY.X]W^-T+T.>71^/!!Q+*"H:6ZY)+,LG'!+#
MU+I=\BR8U?&_JVOG\E(UBZI+/DF;'GP'Y]T\3,%I:TN=J@*#5`G6Y3Q,V8NG
M\;E&)U2:CK*L'95/7>Z/@C$:6,SM2<RJQG-U51B+8F)Q5G-W5L9QTD%H*WI1
MS<G+CJDTKI7EQ77$/.M;95JDA!-H"H/%^\WM7BOHEK)&#5&#5%75-+F63P55
M&>PO?-5C3LP9-NR'L=GDE,'J_G#;=I4X>KHYQN:Z\."1K&56>N:1L)YQPU3@
M1)7G%^*8F2\E0<\TXA,V5^UNZZK&4W82U0&5T\3V)NK^MEFGA394^M`S3QG-
MB]7B[&,R.:J*LILZY78N]Y.:VK1C?D<+-,Z1URMXC'%>^JE2`F00&T!4'B!D
MA"\=[\R/;FZ:H8/?<6^GQ3/5#9[W!R0>L.<&P'8F6LS4D#PX%)42D5_BEAZC
M_4<]4=3[,37A'4NRIU82VX3ZI[JW5P`S51".S'GPM<)XRFQ.>KO?-5A=B3ZZ
MW'15U1-W'U&*'0%7%64W<;+6.-[E:15C:Y-[RY:1#FM;6*:`@!,!`;/U0>&-
M^Q7DO<5NGSN`F<(]J$STK/)N2;_`ZH&E9*FTE[ZJL+LAU9<(PXLK-59&'W4O
MK@$\+NH?B)X)]4]T-KG=J?5'<&JMQ3BJ)N7DQ.V0*?5'8N^ORU5=43<E+5DZ
M*NJ)L4?(M(AC;D5YE4Q"`$`(()@%`;/U0>$BYJ\E[>EI)+&RO!I=]1FF6J*B
MJ#@6IQ!:XZ:=ULRKB$3*@5H">%JIU8G@FRI]2;)X792:C-/JCNCG/BGU1V5O
MJG)]2U2Z4E/$]V#G]J>,YNQ+B=%6,YLQ30$&+(`003`X(`0&S]4'@62H"\S'
MKEIJ@)P6DIIU<06EGS]JK!I6>6_P5,YDH7'55B=8%R>$K,B:9E67H3V8W*:=
M02$\1-F)<52)E""2@(024`)@(`0`@!`;/E0:Z9*SQ7!U>K,J'U158CLH=.>U
M4G5;Y4\+5#I%25+I$RF59D31J+HQ.L=X!5B>S`O)31-D()*`,D$$!*8"0"8"
M`$`(`0&SY4'6NC/9OW4P?_@4OII=85WG\CHRV;=U,&\OI?31U@=I'1CLV[IX
M-Y?2^FC(':4=&.S7NG@WE]+Z:,+M(Z+]FG=+!O+Z7TT8.THZ+MF7='!?+J7T
MT8.THZ+=F/='!?+J3TT\&CHMV8]T,%\NI/306CHLV8]T,$\NI/30!T6;,>Z&
M">74GIH`Z+-F/=#!?+J3TT`=%FS'NA@OEU)Z:`.BS9CW0P7RZD]-`'19LQ[H
M8+Y=2>F@#HLV8]T,%\NI/30!T6;,>Z&"^74GIH`Z+-F/=#!?+J3TT`=%FS'N
MA@OEU)Z:`.BS9CW0P7RZD]-`'19LQ[H8+Y=2>F@#HLV8]T,%\NI/30':$!__
!V3\_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
